ORIGINAL_ARTICLE
Beneficial Effects of Dual Frequency Sonodynamic Therapy and Hematoporphyrin Mesoporous Silica Nanoparticles in the Treatment of Mice Breast Adenocarcinoma
Background: Sonodynamic therapy (SDT) may be a new hopeful non-invasive method for cancer treatment, which incorporates a combination of low-intensity ultrasound and a sonosensitive chemical. The goal of this study was to evaluate the effect of dual-frequency sonication (1 and 3 MHz) and injected Hematoporphyrin encapsulated in mesoporous silica nanoparticles (HP-MSNs) as a sensitizer in the treatment of mice grafted with breast adenocarcinoma.Methods: In this research, one hundred and thirty-two female mice with grafted breast adenocarcinoma were separated into 22 groups including control, sham, 4 groups of sonication 1 or 3 MHz (1 and 2 W/cm2), and 16 groups of SDT with Hematoporphyrin (HP) and HP-MSNs (2.5 and 5 mg/kg). The tumor growth factors and tumor grading were used to assess the treatment management.Results: The results indicate that dual-frequency sonication has a delayed effect on tumor growth. The required time of T5 to the initial volume in all groups of SDT with HP (5 mg/kg) was greater than that in the control group (P<0.05). It was observed that SDT with an injection of HP-MSNs was effective in delaying tumor growth and the time of T2 and T5 was higher than that of other groups (P<0.05). This group had Grade II (intermediate), while others had Grade III (high) malignancy in the histological study of mice breast adenocarcinoma. Conclusion: Our results reveal that dual-frequency SDT therapy with HP-MSN has a delaying tumor growth effect on mice breast adenocarcinoma. Hence, the expansion of minimally invasive methods such as SDT is necessary.
https://jkmu.kmu.ac.ir/article_91888_e2b9a60c40adf02fb8b0e854284a4e48.pdf
2022-03-01
112
122
10.22062/jkmu.2022.91888
breast cancer
Adenocarcinoma
Dual frequency
Sonodynamic therapy
Hematoporphyrin
Mesoporous silica nanoparticle
Monireh
Hoseinzadeh
monireh_hosseinzadeh68@yahoo.com
1
Department of Medical Physics, Semnan University of Medical Sciences, Semnan, Iran
AUTHOR
Majid
Jadidi
jadidim@semums.ac.ir
2
Department of Medical Physics, Semnan University of Medical Sciences, Semnan, Iran
LEAD_AUTHOR
Hadi
Hasanzadeh
3
Department of Medical Physics, Semnan University of Medical Sciences, Semnan, Iran
AUTHOR
Tahereh
Khani
tahereh.khani88@gmail.com
4
Department of Medical Physics, Semnan University of Medical Sciences, Semnan, Iran
AUTHOR
Shoka
Shahryari
shsh9799@yahoo.com
5
Department of Medical Physics, Semnan University of Medical Sciences, Semnan, Iran
AUTHOR
Shima
Saeedi
saeedishima9048@gmail.com
6
Department of Medical Physics, Semnan University of Medical Sciences, Semnan, Iran
AUTHOR
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5-29. doi: 10.3322/caac.21254.
1
Harirchi I, Karbakhsh M, Kashefi A, Momtahen AJ. Breast cancer in Iran: results of a multi-center study. Asian Pac J Cancer Prev. 2004;5(1):24-7. PMID: 15075000.
2
Chen H, Zhou X, Gao Y, Zheng B, Tang F, Huang J. Recent progress in development of new sonosensitizers for sonodynamic cancer therapy. Drug Discov Today. 2014; 19(4):502-9. doi: 10.1016/j.drudis.2014.01.010.
3
Wan GY, Liu Y, Chen BW, Liu YY, Wang YS, Zhang N. Recent advances of sonodynamic therapy in cancer treatment. Cancer Biol Med. 2016 ;13(3):325-38. doi: 10.20892/j.issn.2095-3941.2016.0068.
4
McHale AP, Callan JF, Nomikou N, Fowley C, Callan B. Sonodynamic Therapy: Concept, Mechanism and Application to Cancer Treatment. Adv Exp Med Biol. 2016; 880:429-50. doi: 10.1007/978-3-319-22536-4_22.
5
Rosenthal I, Sostaric JZ, Riesz P. Sonodynamic therapy--a review of the synergistic effects of drugs and ultrasound. Ultrason Sonochem. 2004; 11(6):349-63. doi: 10.1016/j.ultsonch.2004.03.004.
6
Shibaguchi H, Tsuru H, Kuroki M, Kuroki M. Sonodynamic cancer therapy: A non-invasive and repeatable approach using low-intensity ultrasound with a sonosensitizer. Anticancer Res. 2011; 31(7):2425-9. PMID: 21873154.
7
Hasanzadeh H, Mokhtari-Dizaji M, Zahra Bathaie S, Hassan ZM, Shahbazfar AA. Dual-frequency ultrasound activation of nanomicellar doxorubicin in targeted tumor chemotherapy. J Med Ultrason (2001). 2014; 41(2):139-50. doi: 10.1007/s10396-013-0484-x.
8
Suslick KS, McNamara WB, Didenko Y. Hot Spot conditions during multi-bubble cavitation. In: Crum LA, Mason TJ, Reisse JL, Suslick KS. (eds). Sonochemistry and sonoluminescence. NATO ASI Series, vol 524. Dordrecht: Springer; 1999. doi: 10.1007/978-94-015-9215-4_16.
9
Hasanzadeh H, Mokhtari-Dizaji M, Bathaie SZ, Hassan ZM. Effect of local dual frequency sonication on drug distribution from polymeric nanomicelles. Ultrason Sonochem. 2011; 18(5):1165-71. doi: 10.1016/j.ultsonch.2011.03.018.
10
Yumita N, Nishigaki R, Umemura K, Umemura S. Hematoporphyrin as a sensitizer of cell-damaging effect of ultrasound. Jpn J Cancer Res. 1989; 80(3):219-22. doi: 10.1111/j.1349-7006.1989.tb02295.x.
11
Umemura S, Yumita N, Nishigaki R, Umemura K. Sonochemical activation of hematoporphyrin: a potential modality for cancer treatment. IEEE Ultrasonics Symposium; 1989, pp. 955-60 vol.2, doi: 10.1109/ULTSYM.1989.67130.
12
Wang T, Zhang L, Su Z, Wang C, Liao Y, Fu Q. Multifunctional hollow mesoporous silica nanocages for cancer cell detection and the combined chemotherapy and photodynamic therapy. ACS Appl Mater Interfaces. 2011; 3(7):2479-86. doi: 10.1021/am200364e.
13
Paris JL, Cabanas MV, Manzano M, Vallet-Regi Polymer-grafted mesoporous silica nanoparticles as ultrasound-responsive drug carriers. ACS Nano. 2015; 9(11): 11023-33. doi: 10.1021/acsnano.5b04378.
14
Mekaru H, Lu J, Tamanoi F. Development of mesoporous silica-based nanoparticles with controlled release capability for cancer therapy. Adv Drug Deliv Rev. 2015; 95:40-9. doi: 10.1016/j.addr.2015.09.009.
15
Zheng Y, Zhang Y, Ao M, Zhang P, Zhang H, Li P, et al. Hematoporphyrin encapsulated PLGA microbubble for contrast enhanced ultrasound imaging and sonodynamic therapy. J Microencapsul. 2012; 29(5):437-44. doi: 10.3109/02652048.2012.655333.
16
Yang KN, Zhang CQ, Wang W, Wang PC, Zhou JP, Liang XJ. pH-responsive mesoporous silica nanoparticles employed in controlled drug delivery systems for cancer treatment. Cancer Biol Med. 2014; 11(1):34-43. doi: 10.7497/j.issn.2095-3941.2014.01.003.
17
Xu Z, Liu S, Kang Y, Wang M. Glutathione-and pH-responsive nonporous silica prodrug nanoparticles for controlled release and cancer therapy. Nanoscale. 2015; 7(13): 5859-68. doi:10.1039/C5NR00297D.
18
Feng R, Zhao Y, Zhu C, Mason T. Enhancement of ultrasonic cavitation yield by multi-frequency sonication. Ultrasonics sonochemistry 2002; 9(5): 231-6. doi: 10.1016/S1350-4177(02)00083-4.
19
Alamolhoda M, Mokhtari-Dizaji M, Barati AH, Hasanzadeh H. Comparing the in vivo sonodynamic effects of dual- and single-frequency ultrasound in breast adenocarcinoma. J Med Ultrason. 2012; 39(3):115-25. doi: 10.1007/s10396-012-0348-9.
20
Kanthale P M, Brotchie A, Ashokkumar M, Grieser F. Experimental and theoretical investigations on sonoluminescenceunder dual frequency conditions. Ultrasonics Sonochemistry. 2008; 15(4):629-35. doi: 10.1016/j.ultsonch.2007.08.006.
21
Vazquez N I, Gonzalez Z, Ferrari B, Castro Y. Synthesis of mesoporous silica nanoparticles by sol-gel as nanocontainer for future drug delivery applications. BoletinSociedad Espanola Ceramica Vidrio. 2017; 56(3): 139-45. doi: 10.1016/j.bsecv.2017.03.002.
22
Shahbazi MA, Herranz B, Santos HA. Nanostructured porous Si-based nanoparticles for targeted drug delivery. Biomatter. 2012; 2(4):296-312. doi: 10.4161/biom.22347.
23
Bharti C, Nagaich U, Pal AK, Gulati N. Mesoporous silica nanoparticles in target drug delivery system: A review. Int J Pharm Investig. 2015; 5(3):124-33. doi: 10.4103/2230-973X.160844.
24
Yu X, Trase I, Ren M, Duval K, Guo X, Chen Z. Design of nanoparticle-based carriers for targeted drug delivery. Journal Nanomaterials. 2016; 2016:1087250. doi: 10.1155/2016/1087250.
25
Alamolhoda M, Mokhtari-Dizaji M. Evaluation of fractionated and repeated sonodynamic therapy by using dual frequency for murine model of breast adenocarcinoma. J Ther Ultrasound. 2015; 3:10. doi: 10.1186/s40349-015-0031-x.
26
Bloom HJ, and Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957; 11(3):359-77. doi: 10.1038/bjc.1957.43.
27
Barati AH, Mokhtari-Dizaji M, Mozdarani H, Bathaie Z, Hassan ZM. Effect of exposure parameters on cavitation induced by low-level dual-frequency ultrasound. Ultrason Sonochem. 2007; 14(6):783-9. doi: 10.1016/j.ultsonch.2006.12.016.
28
Guan L, Xu G. Damage effect of high-intensity focused ultrasound on breast cancer tissues and their vascularities. World J Surg Oncol. 2016; 14(1):153. doi: 10.1186/s12957-016-0908-3.
29
Yue W, Chen L, Yu L, Zhou B, Yin H, Ren W, et al. Checkpoint blockade and nanosonosensitizer augmented noninvasive sonodynamic therapy combination reduces tumor growth and metastases in mice. NatCommun. 2019; 10:2025. doi: 10.1038/s41467-019-09760-3.
30
Quan-hong L, Shi-hui S, Ya-ping X, Hao Q, Jin-xuan Z, Yao-hui R, et al. Synergistic anti-tumor effect of ultrasound and hematoporphyrin on sarcoma180 cells with special reference to the changes of morphology and cytochrome oxidase activity of tumor cells. J Exp Clin Cancer Res. 2004; 23(2):333-41. PMID: 15354420.
31
Lv Y, Zheng J, Zhou Q, Jia L, Wang C, Liu N, et al. Antiproliferative and apoptosis-inducing effect of exo-Protoporphyrin IX based sonodynamic therapy on human oral squamous cell carcinoma. Sci Rep. 2017; 7:40967. doi:1038/srep40967.
32
Jafari S, Jadidi M, Hasanzadeh H, Khani T, Nasr R, Semnani V. Sonodynamic therapy of mice breast adenocarcinoma with HP-MSN. Iran J Sci Technol Trans Sci. 2020; 44, 651–60. doi.org/10.1007/s40995-020-00893-5.
33
Lee S, Yun HS, Kim SH. The comparative effects of mesoporous silica nanoparticles and colloidal silica on inflammation and apoptosis. Biomaterials. 2011; 32(35):9434-43. doi: 10.1016/j.biomaterials.2011.08.042.
34
Ebrahim Niya A, Mokhtari M, Toliyat T. Evaluating the effects of dual frequency sonication parameters on acoustic cavitation by chemical dosimeter using iodide. Journal of Kerman University of Medical Sciences 2013; 20(2): 179-91.
35
Wang J, Jiao Y, Shao Y. Mesoporous silica nanoparticles for dual-mode chemo-sonodynamic therapy by low-energy ultrasound. Materials (Basel). 2018; 11(10):2041. doi: 10.3390/ma11102041.
36
Yu T, Wang Z, Mason TJ. A review of research into the uses of low level ultrasound in cancer therapy. Ultrason Sonochem. 2004; 11(2):95-103. doi: 10.1016/S1350-4177(03)00157-3.
37
Canavese G, Ancona A, Racca L, Canta M, Dumontel B, Barbaresco F, et al. Nanoparticle-assisted ultrasound: A special focus on sonodynamic therapy against cancer. Chemical Engineering Journal. 2018; 340: 155-72. doi:10.1016/j.cej.2018.01.060.
38
Horise Y, Maeda M, Konishi Y, Okamoto J, Ikuta S, Okamoto Y, et al. Sonodynamic therapy with anticancer micelles and hgh-intensity focused ultrasound in treatment of canine cancer. Front Pharmacol. 2019; 10:545. PMID: 31164823.
39
ORIGINAL_ARTICLE
Evaluation of Levofloxacin-containing Regime in Comparison with Clarithromycin-containing Regime in Eradicating Helicobacter pylori Infection in Kerman
Background: Helicobacter pylori (H.pylori) is the main known cause of gastritis, gastroduodenal ulcer disease, and gastric cancer. Eradication of H.pylori can be an effective method of treatment for peptic ulcer disease and mucosa‐associated lymphoid tissue lymphoma. This study aimed to compare the effectiveness of levofloxacin versus clarithromycin in the eradication of H.pylori.Methods: This randomized clinical trial was conducted on 170 cases with H.pylori infection in Kerman. The participants were randomly allocated to two groups. As the first line therapy, ‘A’ group was treated twice a day with clarithromycin (500mg), pantoprazole (40mg) and amoxicillin (1gr) for 14 days and ‘B’ group was treated twice a day with levofloxacin (250mg), pantoprazole (40mg) and amoxicillin (1gr) for 14 days. Stool H.pylori antigen test was performed one month after the end of treatment. To analyze the data, descriptive and analytical methods and SPSS software version 22 were used.Results: The study cases were comprised of 170 individuals (52.35%female). The mean age of patients in ‘A’ and ‘B’ groups was 42±11.88 and 41±13.75 years, respectively. H.pylori eradication was successful in 61.1% of ‘A’ group and 92.9% of ‘B’ group showing a significant difference (P=0.037). Drug complications were reported in 7.1% of ‘A’ group and 4.7% of ‘B’ group which showed no significant difference between the two groups (P=0.772). The most common drug complication in both groups was abdominal pain (2.3%).Conclusion: The results of this study indicated that levofloxacin-containing regimen was more effective in eradicating H.pylori than the standard clarithromycin triple therapy.
https://jkmu.kmu.ac.ir/article_91889_828bc3cd61e13ad519f60f460e92108a.pdf
2022-03-01
123
133
10.22062/jkmu.2022.91889
Eradication
Helicobacter pylori
Antibiotic
Digestion
Bizhan
Ahmadi
1
Gastroenterology and Hepatology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Masoud
Hajmohammadi
masoudjmd@yahoo.com
2
Department of Internal Medicine, School of Medicine, Afzalipour Hospital, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Ali
Saeed pour
3
Gastroenterology and Hepatology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Motahareh
Zaherara
mzaherara@yahoo.com
4
Department of Medical Basic Sciences, School of Medicine, Bam University of Medical Sciences, Bam, Iran
LEAD_AUTHOR
Sara
Shafieepour
5
1. Gastroenterology and Hepatology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Hoshang
Ghazizadeh Ahsaei
slabgh@yahoo.com
6
Sepehr Laboratory, Kerman, Iran
AUTHOR
Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: Treatment of helicobacter pylori Infection. Am J Gastroenterol. 2017; 112(2):212-39. doi: 10.1038/ajg.2016.563.
1
Fischbach W, Malfertheiner P, Lynen Jansen P, Bolten W, Bornschein J, Buderus S, et al. Verantwortlich für die DGVS. S2k-Leitlinie Helicobacter pylori und gastroduodenale Ulkuskrankheit [S2k-guideline Helicobacter pylori and gastroduodenal ulcer disease]. Z Gastroenterol. 2016; 54(4):327-63. German. doi: 10.1055/s-0042-102967.
2
McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med. 2010; 362(17):1597-604. doi: 10.1056/NEJMcp1001110.
3
NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA. 1994; 272(1):65-9. PMID: 8007082.
4
Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J. Harrison's principles of internal medicine. 17th ed. Internal Medicine Journal. 2015; 38(12):932. doi: 10.1111/j.1445-5994.2008.01837.x.
5
Hsu PI, Lai KH, Hsu PN, Lo GH, Yu HC, Chen WC, et al. Helicobacter pylori infection and the risk of gastric malignancy. Am J Gastroenterol. 2007; 102(4):725-30. doi: 10.1111/j.1572-0241.2006.01109.x.
6
Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: Systematic review and economic analysis. Am J Gastroenterol. 2004; 99(9):1833-55. doi: 10.1111/j.1572-0241.2004.40014.x.
7
Ables AZ, Simon I, Melton ER. Update on Helicobacter pylori treatment. Am Fam Physician. 2007; 75(3):351-8. PMID: 17304866.
8
Chen LT, Lin JT, Tai JJ, Chen GH, Yeh HZ, Yang SS, et al. Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. J Natl Cancer Inst. 2005; 97(18):1345-53. doi: 10.1093/jnci/dji277.
9
Morgner A, Bayerdörffer E, Neubauer A, Stolte M. Malignant tumors of the stomach. Gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori. Gastroenterol Clin North Am. 2000; 29(3):593-607. doi: 10.1016/s0889-8553(05)70132-1.
10
Adamek RJ, Suerbaum S, Pfaffenbach B, Opferkuch W. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin--influence on treatment outcome. Am J Gastroenterol. 1998; 93(3):386-9. doi: 10.1111/j.1572-0241.1998.00386.x.
11
Massarrat S, Saberi-Firoozi M, Soleimani A, Himmelmann GW, Hitzges M, Keshavarz H. Peptic ulcer disease, irritable bowel syndrome and constipation in two populations in Iran. Eur J Gastroenterol Hepatol. 1995; 7(5):427-33. PMID: 7614105.
12
Mégraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004; 53(9):1374-84. doi: 10.1136/gut.2003.022111.
13
Collins J, Ali-Ibrahim A, Smoot DT. Antibiotic therapy for Helicobacter pylori. Med Clin North Am. 2006; 90(6):1125-40. doi: 10.1016/j.mcna.2006.07.002.
14
Mohammadi M, Attaran B, Malekzadeh R, Graham DY. Furazolidone, an Underutilized Drug for H. pylori Eradication: Lessons from Iran. Dig Dis Sci. 2017; 62(8):1890-6. doi: 10.1007/s10620-017-4628-5.
15
Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med. 1995; 333(15):984-91. doi: 10.1056/NEJM199510123331508.
16
Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. European Helicobacter and microbiota study group and consensus panel. management of Helicobacter pylori infection-the maastricht V/florence consensus report. Gut. 2017; 66(1):6-30. doi: 10.1136/gutjnl-2016-312288.
17
Chung JW, Lee GH, Han JH, Jeong JY, Choi KS, Kim DH, et al. The trends of one-week first-line and second-line eradication therapy for Helicobacter pylori infection in Korea. Hepatogastroenterology. 2011; 58(105):246-50. PMID: 21510323.
18
Gisbert JP, Calvet X. Review article: The effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther. 2011; 34(11-12):1255-68. doi: 10.1111/j.1365-2036.2011.04887.x.
19
Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010; 59(8):1143-53. doi: 10.1136/gut.2009.192757.
20
Graham DY. Antibiotic resistance in Helicobacter pylori: Implications for therapy. Gastroenterology. 1998; 115(5):1272-7. doi: 10.1016/s0016-5085(98)70100-3.
21
Vakil N, Vaira D. Non-invasive tests for the diagnosis of H. pylori infection. Rev Gastroenterol Disord. 2004; 4(1):1-6.PMID: 15029105.
22
De Francesco V, Zullo A, Hassan C, Faleo D, Ierardi E, Panella C, et al. Two new treatment regimens for Helicobacter pylori eradication: A randomised study. Dig Liver Dis. 2001; 33(8):676-9. doi: 10.1016/s1590-8658(01)80044-x.
23
Lee H, Hong SN, Min BH, Lee JH, Rhee PL, Lee YC, et al. Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea. Dig Liver Dis. 2015; 47(2):114-8. doi: 10.1016/j.dld.2014.10.014.
24
Hung IF, Chan P, Leung S, Chan FS, Hsu A, But D, et al. Clarithromycin-amoxycillin-containing triple therapy: a valid empirical first-line treatment for Helicobacter pylori eradication in Hong Kong? Helicobacter. 2009; 14(6):505-11. doi: 10.1111/j.1523-5378.2009.00722.x.
25
Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: A meta-analysis. Am J Gastroenterol. 2006;101(3):488-96. doi: 10.1111/j.1572-0241.2006.00637.x.
26
Gopal R, Elamurugan TP, Kate V, Jagdish S, Basu D. Standard triple versus levofloxacin based regimen for eradication of Helicobacter pylori. World J Gastrointest Pharmacol Ther. 2013; 4(2):23-7. doi: 10.4292/wjgpt.v4.i2.23.
27
Goudarzi M, Heidary M, Azad M, Fazeli M, Goudarzi H. Evaluation of antimicrobial susceptibility and integron carriage in Helicobacter pylori isolates from patients. Gastroenterol Hepatol Bed Bench. 2016;9(1):47-52. PMID: 28224028; PMCID: PMC5310800.
28
Haji-Aghamohammadi AA, Bastani A, Miroliaee A, Oveisi S, Safarnezhad S. Comparison of levofloxacin versus clarithromycin efficacy in the eradication of Helicobacter pylori infection. Caspian J Intern Med. 2016; 7(4):267-71. PMID: 27999644.
29
Khademi F, Poursina F, Hosseini E, Akbari M, Safaei HG. Helicobacter pylori in Iran: A systematic review on the antibiotic resistance. Iran J Basic Med Sci. 2015; 18(1):2-7. PMID: 25810869.
30
Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol. 2012; 5:23-34. doi: 10.2147/CEG.S25419.
31
Treiber G, Wittig J, Ammon S, Walker S, van Doorn LJ, Klotz U. Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: A randomized controlled trial (MACLOR study). Arch Intern Med. 2002; 162(2):153-60. doi: 10.1001/archinte.162.2.153.
32
Okada M, Oki K, Shirotani T, Seo M, Okabe N, Maeda K, et al. A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate. J Gastroenterol. 1998; 33(5):640-5. doi: 10.1007/s005350050150.
33
Kongchayanun C, Mahachai V, Pornthisarn B, Amornsawadwattana S, Vilaichone RK. Efficacy of 10-day and 5-day concomitant therapy for Helicobacter pylori eradication in Thai patients with non-ulcer dyspepsia. Gastroenterology. 2011; 140(5):879-83. doi: 10.1016/S0016-5085(11)63653-6.
34
Moradniani M, Mirbeik-Sabzevari Z, Jaferian S, Shafiezadeh S, Ehsani Ardakani MJ, Mirzaee Roozbahany M, et al. Levofloxacin based vs clarithromycin based sequential therapy in helicobacter pylori eradication; a randomized clinical trial. Gastroenterol Hepatol Bed Bench. 2018; 11(1):19-26. PMID: 29564061.
35
Fakheri H, Bari Z, Taghvaei T, Hosseini V, Maleki I, Valizadeh SM, Kazemi A. The efficacy of levofloxacin-based triple therapy for helicobacter pylori eradication after failure with clarithromycin-containing regimens. Govaresh. 2018; 22:261-65.
36
Tirgar Fakheri S, Sadough A, Fakheri H. Comparing Clarithromycin- and Levofloxacin-Containing Triple Therapies for First Line Helicobacter pylori Eradication in Mazandran Province, Iran . J Mazandaran Univ Med Sci. 2019; 29(176):1-9.
37
Tariq H, Patel H, Kamal MU, Abbas N, Ameen M, Azam S, Kumar K, Ravi M, Vootla V, Shaikh D, Amanchi V, Hussain AN, Makker J. Reevaluation of the Efficacy of First Line Regimen for Helicobacter pylori. Clin Exp Gastroenterol. 2020; 13:25-33. doi: 10.2147/CEG.S239343.
38
ORIGINAL_ARTICLE
Which Psychotropic Medicines are Preferred by Iranian Psychiatrists as the most Accessible Ones under Sanctions?
Background: Accessibility of medicines is one of the main building blocks of health. As a consequence of the decision of the US president to withdraw from the Joint Comprehensive Plan of Action, harsh sanctions were instigated on Iran. Legally, medicines were exempted from the sanctions. But in practice, this action has caused serious shortage of medicines including psychotropics in Iran. As a domestic solution, the impact of this shortage on the patients could be mitigated by distributing the most needed medicines in pharmacies closest to public and private psychiatric clinics to reduce patients’ sense of bewilderment. We tried to identify the top 10 psychiatric medicines for this purpose. Methods: Through semi-structured interviews with all the 384 reachable psychiatrists of Iran, face to face or by phone, we prepared a list of psychiatric medicines preferred as priority. Data were analyzed using c2 for relationships with contributing factors and controlling for confounders.Results: Medicines were ranked, and we ended up with a final list of ten. Sertraline ranked first followed by sodium valproate and risperidone. Age and years of experience were correlated with preferences. Comparison with the sales market ranking showed that the latter is mainly influenced by benzodiazepines not prescribed by psychiatrists.Conclusion: We finalized a ranked list of psychiatric medicines useful for the food and drug administration of Iran to consider in distributing psychotropic medicines in the vicinity of public and private clinics. This will ease access and help in mitigating patients’ stress. Other medical groups can follow suit.
https://jkmu.kmu.ac.ir/article_91890_ed1386e1b3fc74a3dd35c17141caa2fe.pdf
2022-03-01
134
138
10.22062/jkmu.2022.91890
Psychotropic medicines
Access to medicines
Iran
US sanctions
Seyed Shahab
Banihashem
1
Department of Psychiatry, Taleghani Hospital Research Development Unit School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
AUTHOR
Mohammad Taghi
Yasamy
yasamy@gmail.com
2
Department of Psychiatry, Taleghani Hospital Research Development Unit School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
LEAD_AUTHOR
Ali
Kheradmand
dr.alikheradmand@yahoo.com
3
Department of Psychiatry, Taleghani Hospital Research Development Unit School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
AUTHOR
Maria
Tavakoli-Ardakani
mariatavakoli@sbmu.ac.ir
4
Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
AUTHOR
Reyhaneh
Jafarian Bahri
r1984jafarian@yahoo.com
5
SBMU Health Cohort Center, TaleghaniHospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
AUTHOR
Mohammad Reza
Sohrabi
m.r.sohrabi@gmail.com
6
Shahid Beheshti University of Medical Sciences, Social Determinants of Health Research Center, Tehran, Iran
AUTHOR
World Health Organization. Monitoring the building blocks of health systems: A handbook of indicators and their measurement strategies. 2010; Available from: https://apps.who.int/iris/handle/10665/258734.
1
Mousavi M, Alavinezhad R, Khazaei M. Psychotherapy approaches of Iranian psychiatrists and psychologists. J Fundam Ment Heal. 2018; 20(3):202-207. doi: 10.22038/JFMH.2018.10693.
2
Khodaei MR, Mirabzadeh A, Shemshadi H, Ashtari Z, Ranjbar M, Feizzadeh G, et al . Pattern of Psychotropic Drug Prescription in the Elderly with Chronic Schizophrenia. Iranian Rehabilitation Journal. 2013; 11(17):20-7.
3
Danaei G, Harirchi I, Sajadi HS, Yahyaei F, Majdzadeh R. The harsh effects of sanctions on Iranian health. Lancet. 2019; 394(10197):468-469. doi: 10.1016/S0140-6736(19)31763-5.
4
Salamat News. Fifty-seven medicines are scarce in Iranian drug market. 18 July 2018; Available from: https://www.salamatnews.com/news/248643. [In Persian].
5
Mahdavi B. Shortage of schizophrenia medicines. 3 March 2021; Available from: https://www.ettelaat.com/mobile/?p=163621&device=phone. [In Persian].
6
S. Department of the Treasury. Iran Sanctions: OFAC FAQs. 3 March 2021; Available from: https://home.treasury.gov/policy-issues/financial-sanctions/faqs/topic/1551.
7
Shams A and reality check team. Iran sanctions: What impact are they having on medicines. BBC. Available from: https://www.bbc.com/news/world-middle-east-49051782.
8
HRV-Human Rights Watch Report. “Maximum Pressure” US economic sanctions harm Iranians` right to health. 3 March 2021; Available from: https://www.ecoi.net/en/document/2019095.html
9
Kheirandish M, Varahrami V, Kebriaeezade A, Cheraghali AM. Impact of economic sanctions on access to noncommunicable diseases medicines in the Islamic Republic of Iran. East Mediterr Health J. 2018; 24(1):42-51. doi: 10.26719/2018.24.1.42.
10
Shahabi S. International sanctions: Sanctions in Iran disrupt cancer care. Nature. 2015; 520(7546):157. doi: 10.1038/520157b.
11
World Health Organization. Pharmacological treatment of mental disorders in primary health care; 2009. Available from: https://www.who.
12
int/publications-detail-redirect/9789241547697.
13
Shargh daily. Shortage of anti-anxiety medicines for psychiatric patients. 19 September 2019; Available from: https://sharghdaily.com/fa/main/print/238993. [In Persian].
14
Salamat News. Psychiatrist wrote a petition to the Minister Of Health on the shortage of medicines. 3 August 2019; Available from: https://www.salamatnews.com/news/277088. [In Persian].
15
Sadeghirad B, Haghdoost AA, Amin-Esmaeili M, Ananloo ES, Ghaeli P, Rahimi-Movaghar A, Talebian E, Pourkhandani A, Noorbala AA, Barooti E. Epidemiology of major depressive disorder in iran: a systematic review and meta-analysis. Int J Prev Med. 2010; 1(2):81-91. PMID: 21566767
16
Grohol JM. Top 25 psychiatric medications for 2018; 12 October 2017. Available from: https://psychcentral.com/blog/top-25-psychiatric-medications-for-2018.
17
ORIGINAL_ARTICLE
The Efficacy of Immunocryosurgery with Combined 2% Niosomal Zinc Sulfate Suspension and Cryotherapy in the Treatment of Verruca vulgaris
ackground: Topical zinc sulfate application has lower efficacy in comparison with intralesional usage, due to less penetration of ionic drug within the epidermis. Niosomes introduce new method of drug delivery with improved penetration and sustained release of medicaments within epidermis. On the other hand, combined cryotherapy with topical immunomodulators can increase the efficacy of cryotherapy with less recurrence rate. In this study, we compared the efficacy of 2% niosomal zinc sulfate suspension with cryotherapy versus combined conventional 2% zinc sulfate and cryotherapy in the treatment of Verruca vulgaris.Methods: This is a triple-blind randomized clinical trial on 60 patients. Patients were randomized in 2 groups including combined 2% niosomal zinc sulfate suspension with cryotherapy versus combined 2% conventional zinc sulfate suspension combined with cryotherapy. The efficacy of treatment was evaluated during the treatment sessions until 12 weeks. Patients were followed for 3 months after the end of the treatment to evaluate recurrence rate. We used chi-square test to evaluate the efficacy of treatment and side effects. Mean number of treatment sessions was evaluated by t-test.Results: Mean number of the treatment sessions for complete remission was 3.66±0.92 and 4.63±0.66, in niosomal group and conventional group, respectively (P=0.001). The rate of complete remission was higher at the 6th and 8th weeks of the treatment in niosomal group compared to conventional group (P=0.001).Conclusion: This study demonstrated significant rapid remission of wart lesions treated with cryotherapy plus 2% niosomal zinc oxide suspension in comparison with cryotherapy plus 2% conventional zinc oxide suspension.
https://jkmu.kmu.ac.ir/article_91891_5a78a2ed5e414d6807c2c59c40e4b54d.pdf
2022-03-01
139
145
10.22062/jkmu.2022.91891
Niosomes
Zinc sulfate
Cryotherapy
Verruca vulgaris
Maryam
Khalili
1
Pathology and Stem Cell Research Center, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Roozbeh
Mehrabadi
mehrabadiroozbeh@gmail.com
2
Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Saman
Mohammadi
sm_750@yahoo.com
3
Pathology and Stem Cell Research Center, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Abbas
Pardakhty
abpardakhty@kmu.ac.ir
4
Pharmaceutics Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Rezvan
Amiri
rezvanamiri1358@yahoo.com
5
Pathology and Stem Cell Research Center, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Mahin
Aflatonian
maaflatoonian@gmail.com
6
Pathology and Stem Cell Research Center, Kerman University of Medical Sciences, Kerman, Iran
LEAD_AUTHOR
Sterling JC, Gibbs S, Haque Hussain SS, Mohd Mustapa MF, Handfield-Jones SE. British association of dermatologists' guidelines for the management of cutaneous warts 2014. Br J Dermatol. 2014; 171(4):696-712. doi: 10.1111/bjd.13310.
1
Iranmanesh B, Khalili M, Zartab H, Amiri R, Aflatoonian M. Laser therapy in cutaneous and genital warts: A review article. Dermatol Ther. 2021; 34(1):e14671. doi: 10.1111/dth.14671.
2
Youn SH, Kwon IH, Park EJ, Kim KH, Kim KJ. A two-week interval is better than a three-week interval for reducing the recurrence rate of hand-foot viral warts after cryotherapy: A retrospective review of 560 hand-foot viral warts patients. Ann Dermatol. 2011; 23(1):53-60. doi: 10.5021/ad.2011.23.1.53.
3
Bourke JF, Berth-Jones J, Hutchinson PE. Cryotherapy of common viral warts at intervals of 1, 2 and 3 weeks. Br J Dermatol. 1995; 132(3):433-6. doi: 10.1111/j.1365-2133.1995.tb08678.x.
4
Song D, Pan L, Zhang M, Wang S. Clinical use of zinc in viral warts: A systematic review of the clinical trials. J Dermatolog Treat. 2021; 1-23. doi: 1080/09546634.2021.1942420.
5
Holmes AM, Song Z, Moghimi HR, Roberts MS. Relative penetration of zinc oxide and zinc ions into human skin after application of different zinc oxide formulations. ACS Nano. 2016; 10(2): 1810-9. doi: 10.1021/acsnano.5b04148.
6
Farajzadeh S, Ahmadi R, Mohammadi S, Pardakhty A, Khalili M, Aflatoonian M. Evaluation of the efficacy of intralesional Glucantime plus niosomal zinc sulphate in comparison with intralesional Glucantime plus cryotherapy in the treatment of acute cutaneous leishmaniasis, a randomized clinical trial. J Parasit Dis. 2018; 42(4):616-20. doi: 10.1007/s12639-018-1044-5.
7
Gaitanis G, Bassukas ID. Immunocryosurgery for non-superficial basal cell carcinomas ≤ 20 mm in maximal diameter: Five-year follow-up. J Geriatr Oncol. 2019; 10(3): 475-8. doi: 10.1016/j.jgo.2018.08.012.
8
Akbari V, Abedi D, Pardakhty A, Sadeghi-Aliabadi H. Release studies on ciprofloxacin loaded non-ionic surfactant vesicles. Avicenna J Med Biotechnol. 2015; 7(2):69-75. PMID: 26140184.
9
Farajzadeh S, Pardakhti A, Mohammadi S, Fadaei F, Khalili M, Mohebbi A, et al. A Randomized clinical trial of using niosomal zinc sulfate plus cryotherapy in comparison with placebo along with cryotherapy in treatment of common wart. Journal of Kerman University of Medical Sciences. 2018; 25(1):1-8.
10
Bagherani N, Smoller BR. An overview of zinc and its importance in dermatology-Part I: Importance and function of zinc in human beings. Glob Dermatol. 2016; 3(5):330-6. doi: 10.15761/GOD.1000186.
11
Gupta M, Mahajan VK, Mehta KS, Chauhan PS. Zinc therapy in dermatology: A review. Dermatol Res Pract. 2014; 2014:709152. doi: 10.1155/2014/709152.
12
Mun JH, Kim SH, Jung DS, Ko HC, Kim BS, Kwon KS, et al. Oral zinc sulfate treatment for viral warts: an open-label study. J Dermatol. 2011; 38(6):541-5. doi: 10.1111/j.1346-8138.2010.01056.x.
13
Mahmoudi H, Ghodsi SZ, Tavakolpour S, Daneshpazhooh M. Cryotherapy plus oral zinc sulfate versus cryotherapy plus placebo to treat common warts: A double blind, randomized, placebo-controlled trial. Int J Womens Dermatol. 2017; 4(2): 87-90. doi: 10.1016/j.ijwd.2017.09.004.
14
Mohamed EE, Tawfik KM, Mahmoud The clinical effectiveness of intralesional injection of 2% zinc sulfate solution in the treatment of common warts. Scientifica (Cairo). 2016; 2016:1082979. doi: 10.1155/2016/1082979.
15
Sharquie KA, Al-Nuaimy AA. Treatment of viral warts by intralesional injection of zinc sulphate. Ann Saudi Med. 2002; 22(1-2):26-8. doi: 10.5144/0256-4947.2002.26.
16
Abd El-Magid WM, Nada EEA, Mossa RA. Intralesional injection of vitamin D3 versus zinc sulfate 2% in treatment of plantar warts: A comparative study. J Dermatolog Treat. 2021; 32(3):355-60. doi: 10.1080/09546634.2019.1656326.
17
El Sayed MH, Sayed FS, Afify AA. Intralesional zinc sulfate 2% vs intralesional vitamin D in plantar warts: A clinicodermoscopic study. Dermatol Ther. 2020; 33(3):e13308. doi: 10.1111/dth.13308.
18
Nofal A, Albalat W, Ismail A, Khattab FM. Immunotherapeutic modalities for the treatment of recalcitrant plantar warts: A comparative study. J Dermatolog Treat. 2020; 9:1-6. doi: 10.1080/09546634.2020.1789540.
19
Khattar JA, Musharrafieh UM, Tamim H, Hamadeh GN. Topical zinc oxide vs. salicylic acid-lactic acid combination in the treatment of warts. Int J Dermatol. 2007; 46(4):427-30. doi: 10.1111/j.1365-4632.2006.03138.x.
20
Songsantiphap C, Asawanonda P. Topical 15% zinc oxide ointment significantly reduces the size of common warts after four weeks: A randomized, triple-blinded, placebo-controlled trial. J Clin Aesthet Dermatol. 2019; 12(9):26-31. PMID: 31641414.
21
Sharquie KE, Khorsheed AA, Al-Nuaimy AA. Topical zinc sulphate solution for treatment of viral warts. Saudi Med J. 2007; 28(9):1418-21. PMID: 17768472.
22
ORIGINAL_ARTICLE
Evaluation of Viral and Bacterial Causes of Ex udative Pharyngitis in 3 to 15-year-old Children referred to the Clinics Affiliated to Kerman University of Medical Sciences
Background: Exudative pharyngitis is one of the common causes of children referral to medical centers. This problem is caused by various bacterial and viral causes. Antibiotics seem to be taken indiscriminately and irrationally. Investigation of bacterial and viral causes is useful for appropriate treatment. This study aimed to compare the bacterial and viral causes of exudative pharyngitis in children aged 3-15 years who referred to the clinics affiliated to Kerman University of Medical Sciences.Methods: The study population consisted of children who presented with fever and sore throat and were diagnosed with exudative pharyngitis. Samples were taken from the nasopharynx with sterile swabs and sent to the laboratory to culture group A beta-hemolytic Streptococcus (GAS) and molecular analysis of common viruses. The resulting information was recorded on the data collection form. Data were analyzed by SPSS version 20 using descriptive statistics, and an inference was made.Results: The mean age of the study group was 7.33 years with a standard deviation of 3.05 and the mean age was 7 years. Most cases (42.6%) referred to the clinics in winter. The most common clinical symptoms were fever (86.9%), sudden onset of the symptoms (77%), sore throat (75.4%), and cough (67.2%), respectively. Seven cases (11.5%) were positive for GAS bacteria. Thirty-two cases (52.5%) were positive for the studied viruses. In housewives, the frequency of positive results in terms of bacteria was significantly lower than that in other occupations. The frequency of virus-positive samples in terms of demographic variables, bacteriological test results in terms of disease symptoms, virology test results in terms of disease symptoms, and comparison of clinical signs and symptoms in the positive group in terms of bacteria and virus were not significant (P > 0.05).Conclusion: Viral causes of exudative pharyngitis are more than bacterial causes. If cultured and laboratory diagnosis is available, it is best to identify the causes of pharyngitis before starting treatment with antibiotics.
https://jkmu.kmu.ac.ir/article_91892_c224e42799ff8ba0b1defdaee07fe094.pdf
2022-03-01
146
151
10.22062/jkmu.2022.91892
children
Pharyngitis
Exudate
Bacterial causes
Viruses
Ali
Hosseininasab
ali4221@yahoo.com
1
Infectious and Tropical Research Center, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Elham
Sharifi
elhamsharifi59@yahoo.com
2
Department of Pediatrics, Emam Khomeini Hospital, Jiroft University of Medical Sciences, Jiroft, Iran
LEAD_AUTHOR
Hamidreza
Molaei
3
Department of Medical Microbiology, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Ali
Khalooei
dr_khalooei@yahoo.com
4
Department of Social Medicine, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Peyvand
Nazeri
5
Laboratory of Microbiology, Afzalipour Hospital, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Kalra MG, Higgins KE, Perez ED. Common questions about streptococcal pharyngitis. Am Fam Physician. 2016; 94(1):24-31. PMID: 27386721.
1
Kruger K, Topfner N, Berner R, Windfuhr J, Oltrogge JH. Guideline group. clinical practice guideline: Sore throat. Dtsch Arztebl Int. 2021; 118:188-94. doi: 10.3238/arztebl.m2021.0121.
2
Flores AR, Caserta MT. Pharyngitis. mandell, douglas, and bennett's principles and practice of infectious diseases. 2015:753-9.
3
Leung TN, Hon KL, Leung AK. Group A Streptococcus disease in Hong Kong children: An overview. Hong Kong Med J. 2018; 24(6):593-601. doi: 10.12809/hkmj187275.
4
Baracco Infections caused by group C and G streptococcus (Streptococcus dysgalactiae subsp. equisimilis and others): Epidemiological and clinical aspects. In Gram-Positive Pathogens. New York: Wiley. 2019. P. 275-83. doi: 10.1128/9781683670131.ch17.
5
Oliver J, Malliya Wadu E, Pierse N, Moreland NJ, Williamson DA, Baker MG. Group A Streptococcus pharyngitis and pharyngeal carriage: A meta-analysis. PLoS Negl Trop Dis. 2018; 12(3): doi: 10.1371/journal.pntd.0006335.
6
Young EH, Panchal RM, Yap AG, Reveles KR. National trends in oral antibiotic prescribing in united states physician offices from 2009 to 2016. Pharmacotherapy. 2020; 40(10):1012-21. doi: 10.1002/phar.2456.
7
Kunnamo A, Korppi M, Helminen M. Tonsillitis in children: Unnecessary laboratory studies and antibiotic use. World J Pediatr. 2016; 12(1):114-7. doi: 10.1007/s12519-015-0054-y.
8
Hoseininasab A, Sinaei R, Bahman-Bijari B, Moeinadini Nasal colonization rate of community and hospital acquired methicillin resistant staphylococcus aureus in hospitalized children. Journal of Kerman University of Medical Sciences. 2012; 19(1):52-62.
9
Marghani A, Algariri K, Ridzuan PM. Prospective influence of phytotherapy on resistant bacterial tonsillitis. J Pure Appl Microbiol. 2019; 13(1):167-78. doi: 22207/JPAM.13.1.17.
10
Takacs A, Szucs D, Terhes G. Lepedekes tonsilla gyermekkorban. Hogyan csokkentheto az indokolatlan antibiotikumfelhasznalas?: Exudative tonsillitis in children. How can we reduce the unnecessary antibiotic consumption?. Orv Hetil. 2020; 161(2):50-5. Hungarian. doi: 10.1556/650.
11
Sun J, Keh-Gong W, Hwang B. Evaluation of the etiologic agents for acute suppurative tonsillitis in children. Zhonghua Yi Xue Za Zhi (Taipei). 2002; 65(5):212-7. PMID: 12166765.
12
Hsieh TH, Chen PY, Huang FL, Wang JD, Wang LC, Lin HK, et al. Are empiric antibiotics for acute exudative tonsillitis needed in children? J Microbiol Immunol Infect. 2011; 44(5):328-32. doi: 10.1016/j.jmii.2010.08.009.
13
Espadas Macia D, Flor Macian EM, Borras R, Poujois Gisbert S, Munoz Bonet JI. Infeccion por estreptococo pyogenes en la edad pediatrica: desde faringoamigdalitis aguda a infecciones invasivas [Streptococcus pyogenes infection in paediatrics: from pharyngotonsillitis to invasive infections]. An Pediatr (Engl Ed). 2018; 88(2):75-81. doi: 10.1016/j.anpedi.2017.02.011.
14
Oliver J, Upton A, Jack SJ, Pierse N, Williamson DA, Baker MG. Distribution of streptococcal pharyngitis and acute rheumatic fever, Auckland, New Zealand, 2010-2016. Emerg Infect Dis. 2020; 26(6):1113-21. doi: 10.3201/eid2606.181462.
15
Robinson Paediatrics: How to manage pharyngitis in an era of increasing antimicrobial resistance. Drugs Context. 2021; 10:2020-11-6. doi: 10.7573/dic.2020-11-6.
16
Klug Peritonsillar abscess: clinical aspects of microbiology, risk factors, and the association with parapharyngeal abscess. Dan Med J. 2017; 64(3):5333. PMID: 28260599.
17
Weber Pharyngitis. Prim Care. 2014; 41(1):91-8. doi: 10.1016/j.pop.2013.10.010.
18
ORIGINAL_ARTICLE
Effect of Surface Treatment on the Bond Strength of Fiber-Reinforced Composite Posts
Background: Bond strength of fiber-reinforced composite (FRC) posts can be influenced by the post surface treatment method. The aim of the present study was to evaluate the effect of surface treatment method on the bond strength of FRC posts.Methods: 40 extracted mandibular premolars with minimum root length of 14 mm were cut from 1 mm above CEJ and root canal treatment was performed on them. Randomly divided into 2 groups: Group 1 surface treatment with hydrogen peroxide (H2O2) 24%, group 2 surface treatment with hydrofluoric acid (HF) 10% and posts in 2 groups cemented with Luxacore cement. The push-out test was performed on 2 mm sections from cervical, medial and apical areas of roots in universal testing machine with speed of 1 mm/min. Bond strength was calculated in megapascal. The failure mode of the specimens was analyzed under stereomicroscope at ×40 magnification. The data were statistically analyzed with SPSS 21 and the results were evaluated by ANOVA, chi2 tests at the significance level of p<0. 05.Results: Bond strength was 22. 13 ± 10. 12 and 21. 27 ± 9. 45 megapascal in group HF and H2O2 respectively. There was no significant difference between two surface treatment methods and bond strength. The most mode of fracture was in cementum-dentin.Conclusion: Based on the result of the present study, surface treatment can affect the bond strength of FRC posts. Further studies are recommended.
https://jkmu.kmu.ac.ir/article_91893_326e062b416deedfaf304da32adad06e.pdf
2022-03-01
152
157
10.22062/jkmu.2022.91893
surface treatment
Fiber post
compressive bond strength
push-out
composite post
Mehrnaz
Karimi-Afshar
1
Department of Prosthodontics, Dental School, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Shahrzad
Taheri
dr.shahrzadtaheri@yahoo.com
2
Department of Prosthodontics, Dental School, Kerman University of Medical Sciences, Kerman, Iran
LEAD_AUTHOR
Faezeh
Haghgooy
faezehaghgooy@yahoo.com
3
Dentist, Private Practice, Kerman, Iran
AUTHOR
Aslan T, Sagsen B, Er Ö, Ustun Y, Cinar F. Evaluation of fracture resistance in root canal-treated teeth restored using different techniques. Niger J Clin Pract. 2018; 21(6):795-800. doi: 10.4103/njcp.njcp_330_17.
1
Sagsen B, Aslan B. Effect of bonded restorations on the fracture resistance of root filled teeth. Int Endod J. 2006; 39(11):900-4. doi: 10.1111/j.1365-2591.2006.01176.x.
2
Stavropoulou AF, Koidis PT. A systematic review of single crowns on endodontically treated teeth. J Dent. 2007; 35(10):761-7. doi: 10.1016/j.jdent.2007.07.004.
3
Schwartz RS, Robbins JW. Post placement and restoration of endodontically treated teeth: a literature review. J Endod. 2004; 30(5):289-301. doi: 10.1097/00004770-200405000-00001.
4
Figueiredo FE, Martins-Filho PR, Faria-E-Silva AL. Do metal post-retained restorations result in more root fractures than fiber post-retained restorations? A systematic review and meta-analysis. J Endod. 2015; 41(3):309-16. doi: 10.1016/j.joen.2014.10.006.
5
Rocca GT, Daher R, Saratti CM, Sedlacek R, Suchy T, Feilzer AJ, et al. Restoration of severely damaged endodontically treated premolars: The influence of the endo-core length on marginal integrity and fatigue resistance of lithium disilicate CAD-CAM ceramic endocrowns. J Dent. 2018; 68:41-50. doi: 10.1016/j.jdent.2017.10.011.
6
Ferrari M, Cagidiaco MC, Goracci C, Vichi A, Mason PN, Radovic I, et al. Long-term retrospective study of the clinical performance of fiber posts. Am J Dent. 2007; 20(5):287-91. PMID: 17993023.
7
Gomes KGF, Faria NS, Neto WR, Colucci V, Gomes EA. Influence of laser irradiation on the push-out bond strength between a glass fiber post and root dentin. J Prosthet Dent. 2018; 119(1):97-102. doi: 10.1016/j.prosdent.2017.01.013.
8
Alnaqbi IOM, Elbishari H, Elsubeihi ES. Effect of Fiber Post-Resin Matrix Composition on Bond Strength of Post-Cement Interface. Int J Dent. 2018; 2018:4751627. doi: 10.1155/2018/4751627.
9
Fokkinga WA, Kreulen CM, Vallittu PK, Creugers NH. A structured analysis of in vitro failure loads and failure modes of fiber, metal, and ceramic post-and-core systems. Int J Prosthodont. 2004; 17(4):476-82. PMID: 15382786.
10
de Sousa Menezes M, Queiroz EC, Soares PV, Faria-e-Silva AL, Soares CJ, Martins LR. Fiber post etching with hydrogen peroxide: effect of concentration and application time. J Endod. 2011; 37(3):398-402. doi: 10.1016/j.joen.2010.11.037.
11
Majeti C, Veeramachaneni C, Morisetty PK, Rao SA, Tummala M. A simplified etching technique to improve the adhesion of fiber post. J Adv Prosthodont. 2014; 6(4):295-301. doi: 10.4047/jap.2014.6.4.295.
12
Perdigão J, Gomes G, Lee IK. The effect of silane on the bond strengths of fiber posts. Dent Mater. 2006; 22(8):752-8. doi: 10.1016/j.dental.2005.11.002.
13
Mishra L, Khan AS, Velo MMAC, Panda S, Zavattini A, Rizzante FAP, et al. Effects of Surface Treatments of Glass Fiber-Reinforced Post on Bond Strength to Root Dentine: A Systematic Review. Materials (Basel). 2020; 13(8):1967. doi: 10.3390/ma13081967.
14
Oguz Ahmet BS, Egilmez F, Ergun G, Cekic Nagas I. Surface treatment effects on bond strength of CAD/CAM fabricated posts to root canal dentin. Am J Dent. 2019; 32(3):113-7. PMID: 31295391.
15
Gomes França FM, Vaneli RC, Conti Cde M, Basting RT, do Amaral FL, Turssi CP. Effect of Chlorhexidine and Ethanol Application on Long-term Push-out Bond Strength of Fiber Posts to Dentin. J Contemp Dent Pract. 2015; 16(7):547-53. doi: 10.5005/jp-journals-10024-1720.
16
Shiratori FK, Valle AL, Pegoraro TA, Carvalho RM, Pereira JR. Influence of technique and manipulation on self-adhesive resin cements used to cement intraradicular posts. J Prosthet Dent. 2013; 110(1):56-60. doi: 10.1016/S0022-3913(13)60341-8.
17
Shillingburg H, Sather D, Wilson E. Fundamentals of fixed prosthodontics. 4th ed. Chicago: Quintessence Pub Co; 2012. Chap 13. p. 200-228.
18
Pahlevan A, Mirzaei M, Akbarian S. Shear bond strength of zirconia post to root dentin with two different cements and comparison with fiber posts. J Islam Dent Assoc IRAN. 2011; 23(1):17-23. [In Persian].
19
Erdemir U, Sar-Sancakli H, Yildiz E, Ozel S, Batur B. An in vitro comparison of different adhesive strategies on the micro push-out bond strength of a glass fiber post. Med Oral Patol Oral Cir Bucal. 2011; 16(4):626-34. doi: 10.4317/medoral.16.e626.
20
Zhang L, Huang L, Xiong Y, Fang M, Chen JH, Ferrari M. Effect of post-space treatment on retention of fiber posts in different root regions using two self-etching systems. Eur J Oral Sci. 2008; 116(3):280-6. doi: 10.1111/j.1600-0722.2008.00536.x.
21
Ubaldini ALM, Benetti AR, Sato F, Pascotto RC, Medina Neto A, Baesso ML, et al. Challenges in luting fibre posts: Adhesion to the post and to the dentine. Dent Mater. 2018; 34(7):1054-62. doi: 10.1016/j.dental.2018.04.001.
22
Sipahi C, Piskin B, Akin GE, Bektas OO, Akin H. Adhesion between glass fiber posts and resin cement: evaluation of bond strength after various pre-treatments. Acta Odontol Scand. 2014; 72(7):509-15. doi: 10.3109/00016357.2013.875586.
23
Aksornmuang J, Chuenarrom C, Chittithaworn N. Effects of various etching protocols on the flexural properties and surface topography of fiber-reinforced composite dental posts. Dent Mater J. 2017; 36(5):614-21. doi: 10.4012/
24
Valdivia AD, Novais VR, Menezes Mde S, Roscoe MG, Estrela C, Soares CJ. Effect of surface treatment of fiberglass posts on bond strength to root dentin. Braz Dent J. 2014; 25(4):314-20. doi: 10.1590/0103-6440201300143.
25
Samimi P, Mortazavi V, Salamat F. Effects of heat treating silane and different etching techniques on glass fiber post push-out bond strength. Oper Dent. 2014; 39(5):E217-24. doi: 10.2341/11-486-L.
26
Schmage P, Cakir FY, Nergiz I, Pfeiffer P. Effect of surface conditioning on the retentive bond strengths of fiberreinforced composite posts. J Prosthet Dent. 2009; 102(6):368-77. doi: 10.1016/S0022-3913(09)60196-7.
27
Kırmalı O, Ustün O, Kapdan A, Kuştarcı A. Evaluation of Various Pretreatments to Fiber Post on the Push-out Bond Strength of Root Canal Dentin. J Endod. 2017 Jul;43(7):1180-1185. doi: 10.1016/j.joen.2017.03.006.
28
Gençoglu N, Sezgin P, Gündoğar M, Şivet C. The effect of surface treatments on the bond strength of fiber post to root canal dentin. Marmara Dent J. 2013; 1(1):35-8. doi: 12990/MDJ2013127.
29
Garcia PP, da Costa RG, Garcia AV, Gonzaga CC, da Cunha LF, Rezende CE, et al. Effect of surface treatments on the bond strength of CAD/CAM fiberglass posts. J Clin Exp Dent. 2018; 10(6):591-7. doi: 10.4317/jced.54904.
30
Fonseca TS, Alfredo E, Vansan LP, Silva RG, Sousa YT, Saquy PC, et al. Retention of radicular posts varying the application technique of the adhesive system and luting agent. Braz Oral Res. 2006; 20(4):347-52. doi: 10.1590/s1806-83242006000400012.
31
Parčina Amižić I, Baraba A, Ionescu AC, Brambilla E, Van Ende A, Miletić I. Bond strength of individually formed and prefabricated fiber-reinforced composite posts. J Adhes Dent. 2019; 21(6):557-65. doi: 10.3290/j.jad.a43649.
32
Amini P, Torabi-Parizi M, Taheri A, Taheri S. The effect of resin cement type and cementation technique on bond strength of fiber posts. Journal of Kerman University of Medical Sciences. 2018; 25(3):206-12.
33
ORIGINAL_ARTICLE
Comparison of the Results of Subtotal Thyroidectomy with Hartley-Dunhill Operation in Surgical Patients
Background: Thyroid resection surgeries used to treat many thyroid diseases may be performed as a total or subtotal thyroidectomy. This study aimed to compare two methods of subtotal thyroidectomy (omission from both sides) with the Hartley-Dunhill procedure in patients with thyroid diseases.Methods: In this retrospective study, the records of all patients who underwent thyroidectomy between 2017 and 2018 were evaluated. Demographic information (age and sex) of patients, initial diagnosis and pathology, type of surgery, serum calcium level on the fourth day after surgery, parathyroid nerve damage, and hematoma were collected using patients’ files. Finally, complications in the two groups were measured.Results: A total number of 100 patients, including 67 female (67%) and 33 male (33%) individuals, were studied. The mean age of patients in the Hartley-Dunhill subtotal thyroidectomy group was 12.65±40.75 years and in the non-Hartley-Dunhill surgery group was 12.86±38.91 years. There was no association between two groups in terms of indications of surgery (P=0.235), postoperative pathology (P=0.754), postoperative hematoma (P=0.11), postoperative recurrence (P=0.714), and the postoperative calcium level (P=0.816). However, the difference in recurrent laryngeal nerve injury occurrence was statistically significant between the groups (P=0.03).Conclusion: Findings of this study showed that there was no significant difference between the groups regarding complications of the surgery, except nerve damage, and the recurrence rate in both methods was clinically pretty low.
https://jkmu.kmu.ac.ir/article_91894_c30bf80dab4046cdbd92a3175591233d.pdf
2022-03-01
158
162
10.22062/jkmu.2022.91894
Hartley-Dunhill
Subtotal
Thyroidectomy
Mohsen
Eshraghi
mohseneshraghi@ymail.com
1
Department of Surgery, School of Medicine, Qom University of Medical Sciences, Qom, Iran
AUTHOR
Mostafa
Vahedian
vahedian58@gmail.com
2
Department of Family and Community Medicine, School of Medicine, Qom University of Medical Sciences, Qom, Iran
AUTHOR
Amrollah
Salimi
dr.salimi.a@gmail.com
3
Department of Surgery, School of Medicine, Qom University of Medical Sciences, Qom, Iran
AUTHOR
Enayatollah
Noori
enoori@muq.ac.ir
4
Department of Surgery, School of Medicine, Qom University of Medical Sciences, Qom, Iran
LEAD_AUTHOR
Sediegheh
Mossavi
5
Department of Surgery, School of Medicine, Qom University of Medical Sciences, Qom, Iran
AUTHOR
Chi SY, Hsei KC, Sheen-Chen SM, Chou FF. A prospective randomized comparison of bilateral subtotal thyroidectomy versus unilateral total and contralateral subtotal thyroidectomy for graves' disease. World J Surg. 2005; 29(2):160-3. doi: 10.1007/s00268-004-7529-7.
1
Stålberg P, Svensson A, Hessman O, Akerström G, Hellman P. Surgical treatment of Graves' disease: Evidence-based approach. World J Surg. 2008; 32(7):1269-77. doi: 10.1007/s00268-008-9497-9.
2
Maschuw K, Schlosser K, Lubbe D, Nies C, Bartsch DK. Total versus near-total thyroidectomy in Graves' disease and their outcome on postoperative transient hypoparathyroidism: Study protocol for a randomized controlled trial? Trials. 2012; 13:234. doi: 10.1186/1745-6215-13-234.
3
Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016; 26(10):1343-421. doi: 10.1089/thy.2016.0229.
4
Porseyedi, B., Zenalinejhad, H., Moslemi-Aghili, S., Aghaei-Afshar, M., Lashkarizadeh, M., Sanjari, M., Yosefzadeh, G., Gozashti, M. Comparison of the Frequency of Recurrent Laryngeal Nerve Injury with and without Exploration of the Nerve in Thyroidectomy. Journal of Kerman University of Medical Sciences, 2012; 19(3): 300-307.
5
Unalp HR, Erbil Y, Akguner T, Kamer E, Derici H, Issever H. Does near total thyroidectomy offer advantage over total thyroidectomy in terms of postoperative hypocalcemia? Int J Surg. 2009; 7(2):120-5. doi: 10.1016/j.ijsu.2008.12.003.
6
Liu J, Bargren A, Schaefer S, Chen H, Sippel RS. Total thyroidectomy: A safe and effective treatment for Graves' disease. J Surg Res. 2011; 168(1):1-4. doi: 10.1016/j.jss.2010.12.038.
7
Erbil Y, Barbaros U, Salmaslioglu A, Yanik BT, Bozbora A, Ozarmagan S. The advantage of near-total thyroidectomy to avoid postoperative hypoparathyroidism in benign multinodular goiter. Langenbecks Arch Surg. 2006; 391(6):567-73. doi: 10.1007/s00423-006-0091-z.
8
Harness JK, Fung L, Thompson NW, Burney RE, McLeod MK. Total thyroidectomy: complications and technique. World J Surg. 1986; 10(5):781-6. doi: 10.1007/BF01655238.
9
Rayes N, Steinmuller T, Schröder S, Klotzler A, Bertram H, Denecke T, et al. Bilateral subtotal thyroidectomy versus hemithyroidectomy plus subtotal resection (Dunhill procedure) for benign goiter: Long-term results of a prospective, randomized study. World J Surg. 2013; 37(1):84-90. doi: 10.1007/s00268-012-1793-8.
10
Reeve TS, Curtin A, Fingleton L, Kennedy P, Mackie W, Porter T, et al. Can total thyroidectomy be performed as safely by general surgeons in provincial centers as by surgeons in specialized endocrine surgical units? Making the case for surgical training. Arch Surg. 1994; 129(8):834-6. doi: 10.1001/archsurg.1994.01420320060011.
11
Barczynski M, Konturek A, Hubalewska-Dydejczyk A, Gołkowski F, Cichon S, Nowak W. Five-year follow-up of a randomized clinical trial of total thyroidectomy versus Dunhill operation versus bilateral subtotal thyroidectomy for multinodular nontoxic goiter. World J Surg. 2010; 34(6):1203-13. doi: 10.1007/s00268-010-0491-7.
12
Mishra A, Agarwal G, Agarwal A, Mishra SK. Safety and efficacy of total thyroidectomy in hands of endocrine surgery trainees. Am J Surg. 1999; 178(5):377-80. doi: 10.1016/s0002-9610(99)00196-8.
13
Lennquist S. The thyroid nodule: Diagnosis and surgical treatment. Surgical Clinics of North America. 1987; 67(2):213-32. doi: 10.1016/S0039-6109(16)44180-0.
14
Steinmuller T, Ulrich F, Rayes N, Lang M, Seehofer D, Tullius SG, et al. Operationsverfahren und risikofaktoren in der therapie der benignen struma multinodosa. ein statistischer vergleich der komplikationshaufigkeit. Chirurg. 2001; 72(12):1453-7. German. doi: 10.1007/s001040170010.
15
ORIGINAL_ARTICLE
Predictive Factors of Recurrent Heart Attack in Patients with Myocardial Infarction: a comprehensive study of various factors
Background: Myocardial infarction (MI) is one of the most common presentations of coronary artery diseases that the age of its prevalence is decreasing. Survivors of MI are at an increased risk of the recurrence of the disease. This study aimed to determine the frequency of recurrent MI and its ppredictive factors in patients with MI.Methods: This descriptive cross-sectional study was conducted on 398 patients with MI referred to Dr. Heshmat hospital in Rasht, the exclusive heart center in Guilan province (north of Iran). Convenience sampling method was used and a valid six-part questionnaire including demographic information, patient's desire to improve knowledge, adherence to the Mediterranean diet, patients' awareness of factors predisposing to re-MI, depression status, and adherence to the therapeutic regimen was employed to collect data. The data were analyzed using descriptive statistics and analytical statistics in SPSS21 at the significance level of P≤ 0.05.Results: The results of the Logistic regression analysis performed by LR method indicated illness duration (OR=0.97, 95% CI=0.95-0.99), history of receiving education (OR=0.1, 95% CI=0.02–0.7), MI type (OR=0.04, 95% CI=0.01–0.34 and OR=0.006, 95% CI=0.001–0.1, respectively for Ant-MI and Post-MI than non-ST-elevation MI) and level of patients' awareness of predisposing factors to MI occurrence (OR=7.31, 95% CI=1.17–45.71, moderate level than good level) as predictors of re-MI.Conclusion: The findings of this study urges policymakers and planners to consider the necessity of applying educational programs related to factors affecting the recurrence of MI.
https://jkmu.kmu.ac.ir/article_91895_dff1fac4e90161977ff3f38d935bd38a.pdf
2022-03-01
163
171
10.22062/jkmu.2022.91895
Myocardial Infarction
Heart attack
recurrent
patients
Fatemeh
Moaddab
f.moaddab89@gmail.com
1
Department of Nursing, Cardiovascular Diseases Research Center, Heshmat Hospital, Guilan University of Medical Sciences, Rasht, Iran & Department of Nursing, Nursing and Midwifery School, Guilan University of Medical Sciences, Rasht, Iran.
AUTHOR
Arsalan
Salari
a.salari55@gmail.com
2
Cardiovascular Diseases Research Center, Department of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
LEAD_AUTHOR
Sarina
Ramtin
3
epartment of Nursing, Nursing and Midwifery School, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Iman
Emadi
moaddab@gums.ac.ir
4
Department of Dentistry, Dentistry School, Guilan University of Medical Sciences, Rasht, Iran
AUTHOR
Zahra
Ahmadnia
zahmadnia1365@gmail.com
5
Cardiovascular Diseases Research Center, Department of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
AUTHOR
Sarrafzadegan N, Mohammmadifard N. Cardiovascular disease in iran in the last 40 years: Prevalence, mortality, morbidity, challenges and strategies for cardiovascular prevention. Arch Iran Med. 2019; 22(4):204-10. PMID: 31126179.
1
Rashidinejad HR, Nasri HR, Salehi M, Moazenzadeh M. Quality of life after Coronary Artery Bypass Grafting (CABG) in older adults. Journal of Kerman University of Medical Sciences. 2019; 26(5):384-9. doi: 10.22062/jkmu.2019.89546.
2
Silverio A, Cavallo P, De Rosa R, Galasso G. Big health data and cardiovascular diseases: A challenge for research, an opportunity for clinical care. Front Med (Lausanne). 2019; 6:36. doi: 10.3389/fmed.2019.00036.
3
Yeo KK, Zheng H, Chow KY, Ahmad A, Chan BPL, Chang HM, et al. Comparative analysis of recurrent events after presentation with an index myocardial infarction or ischaemic stroke. Eur Heart J Qual Care Clin Outcomes. 2017; 3(3):234-42. doi: 10.1093/ehjqcco/qcw048.
4
Perel P, Avezum A, Huffman M, Pais P, Rodgers A, Vedanthan R, et al. Reducing premature cardiovascular morbidity and mortality in people with atherosclerotic vascular disease: The world heart federation roadmap for secondary prevention of cardiovascular disease. Glob Heart. 2015; 10(2):99-110. doi: 10.1016/j.gheart.2015.04.003.
5
Johansson S, Rosengren A, Young K, Jennings E. Mortality and morbidity trends after the first year in survivors of acute myocardial infarction: A systematic review. BMC Cardiovasc Disord. 2017; 17(1):53. doi: 10.1186/s12872-017-0482-9.
6
Piepoli MF, Corrà U, Dendale P, Frederix I, Prescott E, Schmid JP, et al. Challenges in secondary prevention after acute myocardial infarction: A call for action. Eur J Prev Cardiol. 2016; 23(18):1994-2006. doi: 10.1177/2047487316663873.
7
Savarese G. Behavioural interventions to reduce cardiovascular risk: Where do we stand?. Eur Cardiol. 2019; 14(3):139-40. doi: 15420/ecr.2019.14.3.GE3.
8
Haj Hosseini M, Rashidlamir A, Moazzami M, Moazenzadeh M. the effect of eight weeks of aquatic aerobic training on abca1 and abcg1 genes expression in the blood mononuclear cells in women after coronary artery bypass grafting. Journal of Kerman University of Medical Sciences. 2020; 27(3):190-203. doi: 22062/JKMU.2020.90638.
9
Baljani E, Salimi S, Rahimi J, Amanpour E, Parkhashjou M, et al. The effect of education on promoting self efficacy in patients with cardiovascular disease. J Kermanshah Univ Med Sci. 2012;16(3):e78799.
10
Lee YM, Kim RB, Lee HJ, Kim K, Shin MH, Park HK, et al. Relationships among medication adherence, lifestyle modification, and health-related quality of life in patients with acute myocardial infarction: A cross-sectional study. Health Qual Life Outcomes. 2018; 16(1):100. doi: 10.1186/s12955-018-0921-z.
11
Buchanan DM, Arnold SV, Gosch KL, Jones PG, Longmore LS, Spertus JA, et al. Association of smoking status with angina and health-related quality of life after acute myocardial infarction. Circ Cardiovasc Qual Outcomes. 2015; 8(5):493-500. doi: 10.1161/CIRCOUTCOMES.114.001545.
12
Feng HP, Chien WC, Cheng WT, Chung CH, Cheng SM, Tzeng WC. Risk of anxiety and depressive disorders in patients with myocardial infarction: A nationwide population-based cohort study. Medicine (Baltimore). 2016; 95(34):e4464. doi: 10.1097/MD.0000000000004464.
13
Blumenthal JA, Sherwood A, Smith PJ, Watkins L, Mabe S, Kraus WE, et al. Enhancing cardiac rehabilitation with stress management training: A randomized, clinical efficacy trial. Circulation. 2016; 133(14):1341-50. doi: 10.1161/CIRCULATIONAHA.115.018926.
14
Shakeri J, Jaberghaderi N, Rezaei M, Saeedi M, Naleini M, Moloodi A. Psychosocial risk factors in patients with cardio-vascular diseases in Kermanshah. Journal of Kermanshah University of Medical Sciences. 2012; 16(3):246-54. [In Persian]
15
Jan S, Lee SW, Sawhney JP, Ong TK, Chin CT, Kim HS, et al. Catastrophic health expenditure on acute coronary events in Asia: A prospective study. Bull World Health Organ. 2016; 94(3):193-200. doi: 10.2471/BLT.15.158303.
16
Daivadanam M, Thankappan KR, Sarma PS, Harikrishnan S. Catastrophic health expenditure & coping strategies associated with acute coronary syndrome in Kerala, India. Indian J Med Res. 2012; 136(4):585-92. PMID: 23168698.
17
Heydari A, Ziaee E S, Ebrahimzade S. The frequency of rehospitalization and its contributing factors in patient with cardiovascular diseases hospitalized in selected hospitals in Mashhad In 2010. Horizon Med Sci. 2011; 17(2):65-71. [In Persian]
18
Czar ML, Engler MM. Perceived learning needs of patients with coronary artery disease using a questionnaire assessment tool. Heart Lung. 1997; 26(2):109-17. doi: 10.1016/s0147-9563(97)90070-4.
19
Jokelainen J, Timonen M, Keinanen-Kiukaanniemi S, Harkonen P, Jurvelin H, Suija K. Validation of the zung Self-Rating Depression Scale (SDS) in older adults. Scand J Prim Health Care. 2019; 37(3):353-57. doi: 10.1080/02813432.2019.1639923.
20
Habibpour Z. Relationship between mental image and body mass index and depression in high school students in Isfahan. Master Thesis in Psychiatry, Isfahan University of Medical Sciences, Isfahan; 2003. [In Persian]
21
chröder H, Fitó M, Estruch R, Martínez-González MA, Corella D, Salas-Salvadó J, et al. A short screener is valid for assessing Mediterranean diet adherence among older Spanish men and women. J Nutr. 2011; 141(6):1140-5. doi: 10.3945/jn.110.135566.
22
Viscogliosi G, Cipriani E, Liguori ML, Marigliano B, Saliola M, Ettorre E, et al. Mediterranean dietary pattern adherence: Associations with prediabetes, metabolic syndrome, and related microinflammation. Metab Syndr Relat Disord. 2013; 11(3):210-6. doi: 10.1089/met.2012.0168.
23
Kociol RD, Lopes RD, Clare R, Thomas L, Mehta RH, Kaul P, et al. International variation in and factors associated with hospital readmission after myocardial infarction. JAMA. 2012; 307(1):66-74. doi: 10.1001/jama.2011.1926.
24
Sadeghi Afkham M, Ghafoori F, Mardi A, Refahi S. Factors affecting readmission in patients undergoing coronary artery bypasses surgery at tehran heart center. JIUMS. 2019; 26 (5):154-61. [In Persian]
25
Nunes S, Rego G, Nunes R. Difficulties of portuguese patients following acute myocardial infarction: Predictors of readmissions and unchanged lifestyles. Asian Nurs Res (Korean Soc NursSci). 2016; 10(2):150-7. doi: 1016/j.anr.2016.03.005.
26
ORIGINAL_ARTICLE
Multiple Brain Abscesses: An Unusual Case
Brain abscess is a collection of pus with a vascular capsule beginning as a cerebritis at its early stage. The incidence rate of brain abscess is approximately 0.13-0.9 per 100,000 person-year. In 33% of cases, brain abscess is spread hematogenously, mostly with endocarditis (13%), pulmonary infection (8%), or dental infection (5%). Other cases are attributed to recent neurosurgeries (9%) or cranial traumas (14%). Streptococcus and Staphylococcus species are the most common microorganisms causing brain abscesses. The symptoms presented include headache, fever, nausea, vomiting, focal neurologic symptoms, lethargy, and seizure. In this study, a 44-year-old coal worker methadone-abuser man who was admitted with the presentation of altered mental status, headache, imbalance, and vertigo with widespread ring-enhancing lesions in his brain caused by multiple brain abscesses due to solitary lung abscess without pulmonary disease symptoms is reported. Altered consciousness and dysphagia were considered as a cause for his aspiration.
https://jkmu.kmu.ac.ir/article_91897_25cfd25ad3f40a95bc612c6a4aeb9c9f.pdf
2022-03-01
175
182
10.22062/jkmu.2022.91897
Multiple brain abscesses
Hematogenous spread
Confusional state
Ring enhancing lesion
Alireza
Vakilian
alirezavakilian7@gmail.com
1
Department of Neurology, School of Medicine, Non Communicable Disease Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
AUTHOR
Habib
Farahmand
hb.farahmand@gmail.com
2
Department of Radiology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
AUTHOR
Jafar
Ahmadi Kahnali
jafar_ahmady@yahoo.com
3
Department of Radiology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
AUTHOR
Tahereh
Eslammanesh
dr.eslammanesh@yahoo.com
4
Department of Pathology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
AUTHOR
Sajad
Rezvan
clinicalresearch0185@gmail.com
5
Radiology Resident, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
LEAD_AUTHOR
Saeid
Karimi Matloub
saiid.karimi75@yahoo.com
6
Student Research Committee, Faculty of Medicine, Qom University of Medical Sciences, Qom, Iran
AUTHOR
Kragha KO. Multiple Brain Abscesses due to Streptococcus anginosus: Prediction of Mortality by an Imaging Severity Index Score. Case Rep Radiol. 2016; 2016: 7040352. doi: 10.1155/2016/7040352.
1
Sonneville R, Ruimy R, Benzonana N, Riffaud L, Carsin A, Tadié JM, et al. ESCMID Study Group for Infectious Diseases of the Brain (ESGIB). An update on bacterial brain abscess in immunocompetent patients. Clin Microbiol Infect. 2017; 23(9): 614-20. doi: 10.1016/j.cmi.2017.05.004.
2
Brouwer MC, Coutinho JM, van de Beek D. Clinical characteristics and outcome of brain abscess: systematic review and meta-analysis. Neurology. 2014; 82(9): 806-13. doi: 10.1212/WNL.0000000000000172.
3
Lakshmi V, Umabala P, Anuradha K, Padmaja K, Padmasree C, Rajesh A, et al. Microbiological spectrum of brain abscess at a tertiary care hospital in South India: 24-year data and review. Patholog Res Int. 2011; 2011: 583139. doi: 10.4061/2011/583139.
4
Muzumdar D, Jhawar S, Goel A. Brain abscess: an overview. Int J Surg. 2011; 9(2):136-44. doi: 10.1016/j.ijsu.2010.11.005.
5
Bokhari MR, Mesfin FB. Brain Abscess. 2021 Sep 15. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing ;2022. PMID: 28722871.
6
Patel K, Clifford DB. Bacterial brain abscess. Neurohospitalist. 2014; 4(4):196-204. doi: 10.1177/1941874414540684.
7
Ribeiro R, Patrício C, Valejo Coelho MM, Brotas V. A cerebral abscess at first internist glance. BMJ Case Rep. 2015; 2015: bcr2015212162. doi: 10.1136/bcr-2015-212162.
8
Ahmad R. Neurocysticercosis and starry sky appearance on brain imaging. QJM. 2020; 113(4): 283. doi: 10.1093/qjmed/hcz185.
9
Ataka T, Kimura N, Matsubara E. A case of myelin oligodendrocyte glycoprotein-antibody-associated disease presenting with tumefactive demyelinating lesion. Mult Scler Relat Disord. 2020; 43:102191. doi: 10.1016/j.msard.2020.102191.
10
Suzuki T, Okamoto K, Genaki N. A Homogeneously enhancing mass evolving into multiple hemorrhagic and necrotic lesions in amoebic encephalitis with necrotizingvasculitis. Clin Imaging. 2020; 60(1):48-52. doi: 1016/j.clinimag.2019.10.015.
11
Lee GT, Antelo F, Mlikotic AA. Best cases from the AFIP: cerebral toxoplasmosis. Radiographics. 2009; 29(4): 1200-5. doi: 10.1148/rg.294085205.
12
Straehley I, Varada N, Prokop I, Muxen C. Horner Syndrome induced by toxoplasmosis infection in a patient with AIDS and disseminated herpes simplex virus. Am J Ophthalmol Case Rep. 2020; 18: 100679. doi: 10.1016/j.ajoc.2020.100679.
13
ORIGINAL_ARTICLE
Retroperitoneal Ancient schwannoma: A Very Rare Case Report
Background: Ancient schwannoma is an uncommon neoplasm originating from the peripheral nerve sheaths. Ancient schwannoma occurs mostly in head and neck region and its occurrence is very rare in retroperitoneal (about 0.7% to 2.6% of all schwannomas), and despite its benign nature, it can show malignant behaviors and it may be misdiagnosed with sarcomas in some cases. There is nonspecific clinical symptoms and radiologic findings. Evaluation of histology and immunochemistry is necessary for diagnosis, and complete surgical resection is the treatment of choice for schwannoma.Case Report: we report a unique case of retroperitoneal ancient schwannoma in a 50-year-old man with complaint of severe pain in the right flank area for 3 days ago, which was diagnosed with ancient schwannoma after evaluation of the histopathologic and immunohistochemical findings. After surgery, the patient was kept under regular follow-up since last 15 months without any evidence of recurrence.
https://jkmu.kmu.ac.ir/article_91898_69c0d2646bf753b2a24dd01fb6efbe80.pdf
2022-03-01
183
187
10.22062/jkmu.2022.91898
Ancient schwannoma
Retroperitoneal
Nerve sheaths
Khadijeh
Abdal
dr.faribaabdal@yahoo.com
1
Department of Oral and Maxillofacial Pathology, Faculty of Dentistry, Ilam University of Medical Sciences, Ilam, Iran
AUTHOR
Mohammadreza
Hafezi Ahmadi
fariba4479@yahoo.com
2
Department of Pathology, Faculty of Medical, Ilam University of Medical Sciences, Ilam, Iran
LEAD_AUTHOR
Abdal K, Heidari S, Emamverdizadeh P. Schwannoma in gingiva: A Case Report. J Kerman University of Medical Sciences 2019; 26(6): 494-498.
1
Radojkovic M, Mihailovic D, Stojanovic M, et al. Large retroperitoneal schwannoma: a rare cause of chronic back pain. Journal of International Medical Research. 2018;46(8): 3404–3410.
2
Giglio M, Giasotto V, Medica M, Germinale F, Durand F, Queirolo G, et al. Retroperitoneal ancient schwannoma: case report and analysis of clinico-radiological findings. Ann Urol (Paris) 2002; 36(2):104-6. doi: 10.1016/s0003-4401(01)00084-5.
3
Abdal K, Darvishi M, Hafezi Ahmadi M. A case report of malignant peripheral nerve sheath tumor of the breast. Journal of Babol University of Medical Sciences 2019; 21(1):1-5.
4
Al Skaini MS, Haroon H, Sardar A, Bazeed M, Al Zain A, Al Shahrani M, et al. Giant retroperitoneal ancient schwannoma: Is preoperative biopsy always mandatory? Int J Surg Case Rep 2015; 6C:233-6. doi: 10.1016/j.ijscr.2014.08.015.
5
Narasimha A, Kumar MH, Kalyani R, Madan M. Retroperitoneal cystic schwannoma: a case report with review of literature. J Cytol 2010; 27(4):136-9. doi: 10.4103/0970-9371.73299.
6
Wong CS, Chu TY, Tam KF. Retroperitoneal schwannoma: a common tumour in an uncommon site. Hong Kong Med J 2010; 16(1):66-8.
7
Akdemir F, Okulu E, Kayıgil Ö, Yazgan AK. Retroperitoneal ancient schwannoma: a rare case report. J Urol Res 2015; 2(4):1035.
8
Nayyar R, Khattar N, Sood R, Bhardwaj M. Cystic retroperitoneal renal hilar ancient schwannoma: Report of a rare case with atypical presentation masquerading as simple cyst. Indian J Urol 2011; 27(3):404-6. doi: 10.4103/0970-1591.85450.
9
Zhao M, Li X, Wang J, Li W, Huang Z. Retroperitoneal schwannoma treated with percutaneous computed tomography-guided radiofrequency ablation. J Neurosurg Spine 2012; 17(2):173-6. doi: 10.3171/2012.4.SPINE111061.
10
ORIGINAL_ARTICLE
Advances in Stem Cell Therapy Based on Tissue Engineering in the Treatment of Female Infertility with a Focus on POF
Background: In the last few decades, many studies have been done on the treatment of premature ovarian failure. This review was conducted to study different types of treatment with a focus on the 3D culture model of stem cells as a pluripotent source for repairment in regenerative medicine for this disease in recent decades.Methods: To conduct this review, electronic databases of MEDLINE, Scopus, PubMed, and Web of Science were searched using MeSH terms. Only English articles were included, and case reports were excluded. The keywords used for the search were mentioned as the keywords of the paper. Results: To transplant the stem cells into the patient's body, the 3D culture of these cells in vitro and the molecular and cellular aspects of these cells were considered, andtheir success rate and differentiation were compared to granulosa cells or oocytes.Conclusion: The present study aimed to discuss the potential effects of stem cells for regeneration and recovery of ovarian function in premature ovarian failure as a useful therapy.
https://jkmu.kmu.ac.ir/article_91899_47fdfab6712332a7230e9e5790add87b.pdf
2022-03-01
188
202
10.22062/jkmu.2022.91899
Premature Ovarian Failure
Stem Cell Therapy
Three-dimensional Culture
Shadan
Navid
navideshadan@yahoo.com
1
Deptartement of Anatomy, Faculty o Medecine, Social Development & Health Promotion Research Center, Gonabad University of MedicalScience, Gonabad, Iran
LEAD_AUTHOR
Ali
Talebi
alitalebi@skmu.ac.ir
2
School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran & Sexual Health and Fertility Research Center, Shahroud University of Medical Sciences, Shahroud, Iran
AUTHOR
Somayeh
Solhjoo
solhjoo_s@yahoo.com
3
Department of Anatomy, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Tayebeh
Hadigol
anahita.ta_ha@yahoo.com
4
Department of Anatomy, Faculty of Medicine, Alborz University of Medical Sciences, Karaj, Iran
AUTHOR
Zahra
Saadatian
5
Department of Physiology, Faculty of Medicine, Social Development & Health Promotion Research Center, Gonabad University of Medical Sciences, Gonabad, Iran
AUTHOR
Parastoo
Noory
parastoonoory350@gmail.com
6
Department of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Sukcharoen N. Premature ovarian failure. Thai Journal of Obstetrics and Gynaecology. 2020; 14:169-75.
1
Davis SR, Premature ovarian failure. Maturitas. 1996; 23(1):1-8. doi: 10.1016/0378-5122(95)00966-3.
2
Arora P, Polson DW. Diagnosis and management of premature ovarian failure. The Obstetrician & Gynaecologist. 2011; 13(2):67-72. doi: 10.1576/toag.13.2.67.27648.
3
Goswami D, Conway GS. Premature ovarian failure. Hormone Research in Paediatrics. 2007; 68(4):196-202. doi: 10.1159/000102537.
4
Jungari SB, Chauhan BG. Prevalence and Determinants of Premature Menopause among Indian Women: Issues and Challenges Ahead. Health Soc Work. 2017; 42(2):79-86. doi: 10.1093/hsw/hlx010.
5
Sobinoff AP, Sutherland JM, Beckett EL, Stanger SJ, Johnson R, Jarnicki AG, et al. Damaging legacy: maternal cigarette smoking has long-term consequences for male offspring fertility. Hum Reprod. 2014; 29(12):2719-35. doi: 10.1093/humrep/deu235.
6
Ghahremani-Nasab M, Ghanbari E, Jahanbani Y, Mehdizadeh A, Yousefi M. Premature ovarian failure and tissue engineering. J Cell Physiol. 2020; 235(5):4217-26. doi: 10.1002/jcp.29376.
7
Beck-Peccoz P, Persani L. Premature ovarian failure. Orphanet J Rare Dis. 2006; 1:9. doi: 10.1186/1750-1172-1-9.
8
Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996; 14(5):1718-29. doi: 10.1200/JCO.1996.14.5.1718.
9
Bukovsky A. Novel methods of treating ovarian infertility in older and POF women, testicular infertility, and other human functional diseases. Reprod Biol Endocrinol. 2015; 13:10. doi: 10.1186/s12958-015-0001-8.
10
Kovanci E, Schutt AK. Premature ovarian failure: clinical presentation and treatment. Obstet Gynecol Clin North Am. 2015; 42(1):153-61. doi: 10.1016/j.ogc.2014.10.004.
11
Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996; 14(5):1718-29. doi: 10.1200/JCO.1996.14.5.1718.
12
McGuire MM, Bowden W, Engel NJ, Ahn HW, Kovanci E, Rajkovic A. Genomic analysis using high-resolution single-nucleotide polymorphism arrays reveals novel microdeletions associated with premature ovarian failure. Fertil Steril. 2011; 95(5):1595-600. doi: 10.1016/j.fertnstert.2010.12.052.
13
Conway GS. Premature ovarian failure. British Medical Bulletin. 2000; 56(3):643-9. doi: 10.1258/0007142001903445.
14
Chapman C, Cree L, Shelling AN. The genetics of premature ovarian failure: Current perspectives. Int J Womens Health. 2015; 7:799-810. doi: 10.2147/IJWH.S64024.
15
Kalantaridou SN, Davis SR, Nelson LM. Premature ovarian failure. Endocrinol Metab Clin North Am. 1998; 27(4):989-1006. doi: 10.1016/s0889-8529(05)70051-7.
16
Meskhi A, Seif MW. Premature ovarian failure. Curr Opin Obstet Gynecol. 2006; 18(4):418-26. doi: 10.1097/01.gco.0000233937.36554.d3.
17
Janicki SC, Schupf N. Hormonal influences on cognition and risk for Alzheimer's disease. Curr Neurol Neurosci Rep. 2010; 10(5):359-66. doi: 10.1007/s11910-010-0122-6.
18
Muka T, Nano J, Jaspers L, Meun C, Bramer WM, Hofman A, et al. Associations of steroid sex hormones and sex hormone-binding globulin with the risk of type 2 diabetes in women: A population-based cohort study and meta-analysis. Diabetes. 2017; 66(3):577-86. doi: 10.2337/db16-0473.
19
Muka T, Oliver-Williams C, Kunutsor S, Laven JS, Fauser, BC, Chowdhury R, et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality. JAMA Cardiology. 2016; 1(7), 767-76.
20
Sinha P, Kuruba N. Premature ovarian failure. J Obstet Gynaecol. 2007; 27(1):16-9. doi: 10.1080/01443610601016685.
21
Ebrahimi M, Akbari Asbagh F. Pathogenesis and causes of premature ovarian failure: An update. Int J Fertil Steril. 2011; 5(2):54-65. PMID: 24963360.
22
Sonmezer M, Oktay K. Fertility preservation in female patients. Hum Reprod Update. 2004; 10(3):251-66. doi: 10.1093/humupd/dmh021.
23
Rebar RW. Premature ovarian failure. Obstet Gynecol. 2009; 113(6):1355-63. doi: 10.1097/AOG.0b013e3181a66843.
24
Ramirez JM, Rodriguez FA, Echeverria MI, Vargas AL, Calderon AE, Miatello RM, Renna NF. SHOX duplication and tall stature in a patient with Xq deletion and vascular disease. Case Rep Gene 2019; 2019: 2691820. doi: 10.1155/2019/2691820.
25
Tran TN, Schimenti JC. A segregating human allele of SPO11 modeled in mice disrupts timing and amounts of meiotic recombination, causing oligospermia and a decreased ovarian reserve†. Biol Reprod. 2019; 101(2):347-59. doi: 10.1093/biolre/ioz089.
26
Inagaki A, Schoenmakers S, Baarends WM. DNA double strand break repair, chromosome synapsis and transcriptional silencing in meiosis. Epigenetics. 2010; 5(4):255-66. doi: 10.4161/epi.5.4.11518.
27
May-Panloup P, Chretien MF, Malthiery Y, Reynier P. Mitochondrial DNA in the oocyte and the developing embryo. Curr Top Dev Biol. 2007; 77:51-83. doi: 10.1016/S0070-2153(06)77003-X.
28
Van Blerkom J, Davis PW, Lee J. ATP content of human oocytes and developmental potential and outcome after In Vitro fertilization and embryo transfer. Hum Reprod. 1995; 10(2):415-24. doi: 10.1093/oxfordjournals.humrep.a135954.
29
Jankowska K. Premature ovarian failure. Prz Menopauzalny. 2017; 16(2):51-6. doi: 10.5114/pm.2017.68592.
30
May-Panloup P, Chrétien MF, Jacques C, Vasseur C, Malthièry Y, Reynier P. Low oocyte mitochondrial DNA content in ovarian insufficiency. Hum Reprod. 2005; 20(3):593-7. doi: 10.1093/humrep/deh667.
31
Yazdekhasti H, Hosseini MA, Rajabi Z, Parvari S, Salehnia M, Koruji M, et al. Improved isolation, proliferation, and differentiation capacity of mouse ovarian putative stem cells. Cell Reprogram. 2017; 19(2):132-44. doi: 10.1089/cell.2016.0054.
32
Johnson J, Canning J, Kaneko T, Pru JK, Tilly JL. Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature. 2004; 428(6979):145-50. doi: 10.1038/nature02316.
33
Bukovsky A, Gupta SK, Virant-Klun I, Upadhyaya NB, Copas P, Van Meter SE, et al. Study origin of germ cells and formation of new primary follicles in adult human and rat ovaries. Methods Mol Biol. 2008; 450:233-65. doi: 10.1007/978-1-60327-214-8_16.
34
Bukovsky A. Ovarian stem cell niche and follicular renewal in mammals. Anat Rec (Hoboken). 2011; 294(8):1284-306. doi: 10.1002/ar.21422.
35
Bui HT, Van Thuan N, Kwon DN, Choi YJ, Kang MH, Han JW, et al. Identification and characterization of putative stem cells in the adult pig ovary. Development. 2014; 141(11):2235-44. doi: 10.1242/dev.104554.
36
Khosravi-Farsani S, Amidi F, Habibi Roudkenar M, Sobhani A. Isolation and enrichment of mouse female germ line stem cells. Cell J. 2015; 16(4):406-15. doi: 10.22074/cellj.2015.487.
37
Yazdekhasti H, Rajabi Z, Parvari S, Abbasi M. Used protocols for isolation and propagation of ovarian stem cells, different cells with different traits. J Ovarian Res. 2016; 9:68. doi: 10.1186/s13048-016-0274-3.
38
Peng Q, Qin J, Zhang Y, Cheng X, Wang X, Lu W, et al. Autophagy maintains the stemness of ovarian cancer stem cells by FOXA2. J Exp Clin Cancer Res. 2017; 36:171. doi: 10.1186/s13046-017-0644-8.
39
Parte SC, Batra SK, Kakar SS. Characterization of stem cell and cancer stem cell populations in ovary and ovarian tumors. J Ovarian Res. 2018; 11(1):69. doi: 10.1186/s13048-018-0439-3.
40
Witt AE, Lee CW, Lee TI, Azzam DJ, Wang B, Caslini C, et al. Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer. Oncogene. 2017; 36(12):1707-20. doi: 10.1038/onc.2016.337.
41
Kenda Suster N, Virant-Klun I. Presence and role of stem cells in ovarian cancer. World J Stem Cells. 2019; 11(7):383-97. doi: 10.4252/wjsc.v11.i7.383.
42
Ye H, Zheng T, Li W, Li X, Fu X, Huang Y, et al. Ovarian stem cell nests in reproduction and ovarian aging. Cell Physiol Biochem. 2017; 43(5):1917-25. doi: 10.1159/000484114.
43
Parte S, Virant-Klun I, Patankar M, Batra SK, Straughn A, Kakar SS. PTTG1: A unique regulator of stem/cancer stem cells in the ovary and ovarian cancer. Stem Cell Rev Rep. 2019; 15(6):866-79. doi: 10.1007/s12015-019-09911-5.
44
Virant-Klun I, Skerl P, Novakovic S, Vrtacnik-Bokal E, Smrkolj S. Similar population of CD133 + and DDX4 + VSEL-like stem cells sorted from human embryonic stem cell, ovarian, and ovarian cancer ascites cell cultures: The real embryonic stem cells? Cells. 2019; 8(7):706. doi: 10.3390/cells8070706.
45
Kim WT, Ryu CJ. Cancer stem cell surface markers on normal stem cells. BMB Rep. 2017; 50(6):285-98. doi: 10.5483/bmbrep.2017.50.6.039.
46
Noory P, Navid S. Premature ovarian failure treatments: A review study with focus on stem cell therapy as pluripotent source for repairment in regenerative medicine. Austin Med Sci. 2018; 3(2):1027.
47
Noory P, Navid S, Zanganeh BM, Talebi A, Borhani-Haghighi M, Gholami K, et al. Human menstrual blood stem cell-derived granulosa cells participate in ovarian follicle formation in a rat model of premature ovarian failure In Vivo. Cell Reprogram. 2019; 21(5):249-59. doi: 10.1089/cell.2019.0020.
48
Manshadi MD, Navid S, Hoshino Y, Daneshi E, Noory P, Abbasi M. The effects of human menstrual blood stem cells-derived granulosa cells on ovarian follicle formation in a rat model of premature ovarian failure. Microsc Res Tech. 2019; 82(6):635-42. doi: 10.1002/jemt.23120.
49
Sheikhansari G, Aghebati-Maleki L, Nouri M, Jadidi-Niaragh F, Yousefi M. Current approaches for the treatment of premature ovarian failure with stem cell therapy. Biomed Pharmacother. 2018; 102:254-62. doi: 10.1016/j.biopha.2018.03.056.
50
Gargett CE. Stem cells in gynaecology. Aust N Z J Obstet Gynaecol. 2004; 44(5):380-6. doi: 10.1111/j.1479-828X.2004.00290.x.
51
Lai D, Wang F, Dong Z, Zhang Q. Skin-derived mesenchymal stem cells help restore function to ovaries in a premature ovarian failure mouse model. PLoS One. 2014; 9(5):98749. doi: 10.1371/journal.pone.0098749.
52
Liu T, Li Q, Wang S, Chen C, Zheng J. Transplantation of ovarian granulosa‑like cells derived from human induced pluripotent stem cells for the treatment of murine premature ovarian failure. Mol Med Rep. 2016; 13(6):5053-8. doi: 10.3892/mmr.2016.5191.
53
He Y, Chen D, Yang L, Hou Q, Ma H, Xu X. The therapeutic potential of bone marrow mesenchymal stem cells in premature ovarian failure. Stem Cell Res Ther. 2018; 9(1):263. doi: 10.1186/s13287-018-1008-9.
54
Henningson CT Jr, Stanislaus MA, Gewirtz AM. Embryonic and adult stem cell therapy. J Allergy Clin Immunol. 2003; 111(2):745-53. doi: 10.1067/mai.2003.133.
55
Gargett CE. Identification and characterisation of human endometrial stem/progenitor cells. Aust N Z J Obstet Gynaecol. 2006; 46(3):250-3. doi: 10.1111/j.1479-828X.2006.00582.x.
56
Woods DC, White YA, Niikura Y, Kiatpongsan S, Lee HJ, Tilly JL. Embryonic stem cell-derived granulosa cells participate in ovarian follicle formation In Vitro and in vivo. Reprod Sci. 2013; 20(5):524-35. doi: 10.1177/1933719113483017.
57
Liu T, Huang Y, Guo L, Cheng W, Zou G. CD44+/CD105+ human amniotic fluid mesenchymal stem cells survive and proliferate in the ovary long-term in a mouse model of chemotherapy-induced premature ovarian failure. Int J Med Sci. 2012; 9(7):592-602. doi: 10.7150/ijms.4841.
58
Sun M, Wang S, Li Y, Yu L, Gu F, Wang C, et al. Adipose-derived stem cells improved mouse ovary function after chemotherapy-induced ovary failure. Stem Cell Res Ther. 2013; 4(4):80. doi: 10.1186/scrt231.
59
Liu T, Huang Y, Zhang J, Qin W, Chi H, Chen J, et al. Transplantation of human menstrual blood stem cells to treat premature ovarian failure in mouse model. Stem Cells Dev. 2014; 23(13):1548-57. doi: 10.1089/scd.2013.0371.
60
Wang Z, Wang Y, Yang T, Li J, Yang X. Study of the reparative effects of menstrual-derived stem cells on premature ovarian failure in mice. Stem Cell Res Ther. 2017; 8(1):11. doi: 10.1186/s13287-016-0458-1.
61
Lai D, Wang F, Yao X, Zhang Q, Wu X, Xiang C. Human endometrial mesenchymal stem cells restore ovarian function through improving the renewal of germline stem cells in a mouse model of premature ovarian failure. J Transl Med. 2015; 13:155. doi: 10.1186/s12967-015-0516-y.
62
Kucia M, Reca R, Campbell FR, Zuba-Surma E, Majka M, Ratajczak J, et al. A population of very small embryonic-like (VSEL) CXCR4(+) SSEA-1(+) Oct-4+ stem cells identified in adult bone marrow. Leukemia. 2006; 20(5):857-69. doi: 10.1038/sj.leu.2404171.
63
Barry FP, Murphy JM. Mesenchymal stem cells: Clinical applications and biological characterization. Int J Biochem Cell Biol. 2004; 36(4):568-84. doi: 10.1016/j.biocel.2003.11.001.
64
Elfayomy AK, Almasry SM, El-Tarhouny SA, Eldomiaty MA. Human umbilical cord blood-mesenchymal stem cells transplantation renovates the ovarian surface epithelium in a rat model of premature ovarian failure: Possible direct and indirect effects. Tissue Cell. 2016; 48(4):370-82. doi: 10.1016/j.tice.2016.05.001.
65
Waller EK, Olweus J, Lund-Johansen F, Huang S, Nguyen M, Guo GR, Terstappen L. The "common stem cell" hypothesis reevaluated: Human fetal bone marrow contains separate populations of hematopoietic and stromal progenitors. Blood. 1995; 85(9):2422-35. PMID: 7537114.
66
Li J, Mao Q, He J, She H, Zhang Z, Yin C. Human umbilical cord mesenchymal stem cells improve the reserve function of perimenopausal ovary via a paracrine mechanism. Stem Cell Res Ther. 2017; 8(1):55. doi: 10.1186/s13287-017-0514-5.
67
Song D, Zhong Y, Qian C, Zou Q, Ou J, Shi Y, et al. Human umbilical cord mesenchymal stem cells therapy in cyclophosphamide-induced premature ovarian failure rat model. Biomed Res Int. 2016; 2016:2517514. doi: 10.1155/2016/2517514.
68
Chen X, Wang Q, Li X, Wang Q, Xie J, Fu X. Heat shock pretreatment of mesenchymal stem cells for inhibiting the apoptosis of ovarian granulosa cells enhanced the repair effect on chemotherapy-induced premature ovarian failure. Stem Cell Res Ther. 2018; 9(1):240. doi: 10.1186/s13287-018-0964-4.
69
Zhang H, Luo Q, Lu X, Yin N, Zhou D, Zhang L, et al. Effects of hPMSCs on granulosa cell apoptosis and AMH expression and their role in the restoration of ovary function in premature ovarian failure mice. Stem Cell Res Ther. 2018; 9(1):20. doi: 10.1186/s13287-017-0745-5.
70
Wang Z, Wei Q, Wang H, Han L, Dai H, Qian X, et al. Mesenchymal stem cell therapy using human umbilical cord in a rat model of autoimmune-induced premature ovarian failure. Stem Cells Int. 2020; 2020:3249495. doi: 10.1155/2020/3249495.
71
Lu X, Cui J, Cui L, Luo Q, Cao Q, Yuan W, et al. The effects of human umbilical cord-derived mesenchymal stem cell transplantation on endometrial receptivity are associated with Th1/Th2 balance change and uNK cell expression of uterine in autoimmune premature ovarian failure mice. Stem Cell Res Ther. 2019; 10(1):214. doi: 10.1186/s13287-019-1313-y.
72
Badawy A, Sobh MA, Ahdy M, Abdelhafez MS. Bone marrow mesenchymal stem cell repair of cyclophosphamide-induced ovarian insufficiency in a mouse model. Int J Womens Health. 2017; 9:441-7. doi: 10.2147/IJWH.S134074.
73
Xiao GY, Cheng CC, Chiang YS, Cheng WT, Liu IH, Wu SC. Exosomal miR-10a derived from amniotic fluid stem cells preserves ovarian follicles after chemotherapy. Sci Rep. 2016; 6:23120. doi: 10.1038/srep23120.
74
Li J, Yu Q, Huang H, Deng W, Cao X, Adu-Frimpong M, et al. Human chorionic plate-derived mesenchymal stem cells transplantation restores ovarian function in a chemotherapy-induced mouse model of premature ovarian failure. Stem Cell Res Ther. 2018; 9(1):81. doi: 10.1186/s13287-018-0819-z.
75
Li H, Zhao W, Wang L, Luo Q, Yin N, Lu X, et al. Human placenta-derived mesenchymal stem cells inhibit apoptosis of granulosa cells induced by IRE1α pathway in autoimmune POF mice. Cell Biol Int. 2019; 43(8):899-909. doi: 10.1002/cbin.11165.
76
Yin N, Zhao W, Luo Q, Yuan W, Luan X, Zhang H. Restoring ovarian function with human placenta-derived mesenchymal stem cells in autoimmune-induced premature ovarian failure mice mediated by treg cells and associated cytokines. Reprod Sci. 2018; 25(7):1073-82. doi: 10.1177/1933719117732156.
77
Jung D, Xiong J, Ye M, Qin X, Li L, Cheng S, et al. In vitro differentiation of human embryonic stem cells into ovarian follicle-like cells. Nat Commun. 2017; 8:15680. doi: 10.1038/ncomms15680.
78
Lai D, Guo Y, Zhang Q, Chen Y, Xiang C. Differentiation of human menstrual blood-derived endometrial mesenchymal stem cells into oocyte-like cells. Acta Biochim Biophys Sin (Shanghai). 2016; 48(11):998-1005. doi: 10.1093/abbs/gmw090.
79
Hu X, Lu H, Cao S, Deng YL, Li QJ, Wan Q, et al. Stem cells derived from human first-trimester umbilical cord have the potential to differentiate into oocyte-like cells In Vitro. Int J Mol Med. 2015; 35(5):1219-29. doi: 10.3892/ijmm.2015.2132.
80
Yu X, Wang N, Qiang R, Wan Q, Qin M, Chen S, et al. Human amniotic fluid stem cells possess the potential to differentiate into primordial follicle oocytes In Vitro. Biol Reprod. 2014; 90(4):73. doi: 10.1095/biolreprod.113.112920.
81
Qiu P, Bai Y, Pan S, Li W, Liu W, Hua J. Gender depended potentiality of differentiation of human umbilical cord mesenchymal stem cells into oocyte-Like cells In Vitro. Cell Biochem Funct. 2013; 31(5):365-73. doi: 10.1002/cbf.2981.
82
Sun R, Sun YC, Ge W, Tan H, Cheng SF, Yin S, et al. The crucial role of Activin A on the formation of primordial germ cell-like cells from skin-derived stem cells In Vitro. Cell Cycle. 2015; 14(19):3016-29. doi: 10.1080/15384101.2015.1078031.
83
de Souza GB, Costa J, da Cunha EV, Passos J, Ribeiro RP, Saraiva M, et al. Bovine ovarian stem cells differentiate into germ cells and oocyte-like structures after culture In Vitro. Reprod Domest Anim. 2017; 52(2):243-50. doi: 10.1111/rda.12886.
84
Lee YM, Kim TH, Lee JH, Lee WJ, Jeon RH, Jang SJ, et al. Overexpression of Oct4 in porcine ovarian stem/stromal cells enhances differentiation of oocyte-like cells In Vitro and ovarian follicular formation in vivo. J Ovarian Res. 2016; 9:24. doi: 10.1186/s13048-016-0233-z.
85
Asgari HR, Akbari M, Abbasi M, Ai J, Korouji M, Aliakbari F, et al. Human Wharton's jelly-derived mesenchymal stem cells express oocyte developmental genes during co-culture with placental cells. Iran J Basic Med Sci. 2015; 18(1):22-9. PMID: 25810872.
86
Ge W, Ma HG, Cheng SF, Sun YC, Sun LL, Sun X, et al. Differentiation of early germ cells from human skin-derived stem cells without exogenous gene integration. Sci Rep. 2015; 5:13822. doi: 10.1038/srep13822.
87
Dyce PW, Wen L, Li J. In Vitro germline potential of stem cells derived from fetal porcine skin. Nat Cell Biol. 2006; 8(4):384-90. doi: 10.1038/ncb1388.
88
Dyce PW, Shen W, Huynh E, Shao H, Villagomez DA, Kidder GM, et al. Analysis of oocyte-like cells differentiated from porcine fetal skin-derived stem cells. Stem Cells Dev. 2011; 20(5):809-19. doi: 10.1089/scd.2010.0395.
89
Costa JJDN, de Souza GB, Bernardo JMP, Ribeiro RP, Passos JRS, Bezerra FTG, et al. Expression of markers for germ cells and oocytes in cow dermal fibroblast treated with 5-azacytidine and cultured in differentiation medium containing BMP2, BMP4 or follicular fluid. Zygote. 2017; 25(3):341-57. doi: 10.1017/S0967199417000211.
90
Bahmanpour S, Zarei Fard N, Talaei-Khozani T, Hosseini A, Esmaeilpour T. Effect of BMP4 preceded by retinoic acid and co-culturing ovarian somatic cells on differentiation of mouse embryonic stem cells into oocyte-like cells. Dev Growth Differ. 2015; 57(5):378-88. doi: 10.1111/dgd.12217.
91
Sun B, Ma Y, Wang F, Hu L, Sun Y. miR-644-5p carried by bone mesenchymal stem cell-derived exosomes targets regulation of p53 to inhibit ovarian granulosa cell apoptosis. Stem Cell Res Ther. 2019; 10:360. doi: 10.1186/s13287-019-1442-3.
92
Zhang Q, Sun J, Huang Y, Bu S, Guo Y, Gu T, et al. Human amniotic epithelial cell-derived exosomes restore ovarian function by transferring micrornas against apoptosis. Mol Ther Nucleic Acids. 2019; 16:407-18. doi: 10.1016/j.omtn.2019.03.008.
93
Yang M, Lin L, Sha C, Li T, Zhao D, Wei H, et al. Bone marrow mesenchymal stem cell-derived exosomal miR-144-5p improves rat ovarian function after chemotherapy-induced ovarian failure by targeting PTEN. Lab Invest. 2020; 100(3):342-52. doi: 10.1038/s41374-019-0321-y.
94
Navid S, Abbasi M, Hoshino Y. The effects of melatonin on colonization of neonate spermatogonial mouse stem cells in a three-dimensional soft agar culture system. Stem Cell Res Ther. 2017; 8(1):233. doi: 10.1186/s13287-017-0687-y.
95
Gholami K, Pourmand G, Koruji M, Sadighigilani M, Navid S, Izadyar F, et al. Efficiency of colony formation and differentiation of human spermatogenic cells in two different culture systems. Reprod Biol. 2018; 18(4):397-403. doi: 10.1016/j.repbio.2018.09.006.
96
He X. Microfluidic encapsulation of ovarian follicles for 3D culture. Ann Biomed Eng. 2017; 45(7):1676-84. doi: 10.1007/s10439-017-1823-7.
97
Chiti MC, Dolmans MM, Donnez J, Amorim CA. Fibrin in reproductive tissue engineering: a review on its application as a biomaterial for fertility preservation. Ann Biomed Eng. 2017; 45(7):1650-63. doi: 10.1007/s10439-017-1817-5.
98
Ding L, Yan G, Wang B, Xu L, Gu Y, Ru T, et al. Transplantation of UC-MSCs on collagen scaffold activates follicles in dormant ovaries of POF patients with long history of infertility. Sci China Life Sci. 2018; 61(12):1554-65. doi: 10.1007/s11427-017-9272-2.
99
Xu M, Barrett SL, West-Farrell E, Kondapalli LA, Kiesewetter SE, Shea LD, et al. In vitro grown human ovarian follicles from cancer patients support oocyte growth. Hum Reprod. 2009; 24(10):2531-40. doi: 10.1093/humrep/dep228.
100
Bharti D, Jang SJ, Lee SY, Lee SL, Rho GJ. In Vitro generation of oocyte like cells and their in vivo efficacy: How far we have been succeeded. Cells. 2020; 9(3):557. doi: 10.3390/cells9030557.
101
Ranganath SH, Levy O, Inamdar MS, Karp JM. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell. 2012; 10(3):244-58. doi: 10.1016/j.stem.2012.02.005.
102
Zhang Z, Wang JA, Xu Y, Jiang Z, Wu R, Wang L, et al. Menstrual blood derived mesenchymal cells ameliorate cardiac fibrosis via inhibition of endothelial to mesenchymal transition in myocardial infarction. Int J Cardiol. 2013; 168(2):1711-4. doi: 10.1016/j.ijcard.2013.03.126.
103
Wang Z, Wang Y, Yang T, Li J, Yang X. Study of the reparative effects of menstrual-derived stem cells on premature ovarian failure in mice. Stem Cell Res Ther. 2017; 8(1):11. doi: 10.1186/s13287-016-0458-1.
104
Liu R, Zhang X, Fan Z, Wang Y, Yao G, Wan X, et al. Human amniotic mesenchymal stem cells improve the follicular microenvironment to recover ovarian function in premature ovarian failure mice. Stem Cell Res Ther. 2019; 10(1):299. doi: 10.1186/s13287-019-1315-9.
105
Tkach M, Thery C. Communication by Extracellular Vesicles: Where we are and where we need to go. Cell. 2016; 164(6):1226-32. doi: 10.1016/j.cell.2016.01.043.
106
Liu M, Qiu Y, Xue Z, Wu R, Li J, Niu X, ... Wu Q. Small extracellular vesicles derived from embryonic stem cells restore ovarian function of premature ovarian failure through PI3K/AKT signaling pathway. Stem Cell Res Ther. 2020; 11:3. doi: 10.1186/s13287-019-1508-2.
107
Zhao YX, Chen SR, Su PP, Huang FH, Shi YC, Shi QY, Lin S. Using Mesenchymal Stem Cells to Treat Female Infertility: An Update on Female Reproductive Diseases. Stem Cells Int. 2019; 2019: 9071720. doi: 1155/2019/9071720.
108
Ghahremani-Nasab M, Ghanbari E, Jahanbani Y, Mehdizadeh A, Yousefi M. Premature ovarian failure and tissue engineering. J Cell Physiol. 2020; 235(5):4217-26. doi: 10.1002/jcp.29376.
109
Khosravizadeh Z, Rashidi Z, Talebi A, Khodamoradi K, Hassanzadeh G. The role of mitochondria in premature ovarian failure: A review. J Contemp Med Sci. 2020. 6(1):1-7. doi: 10.22317/jcms.v6i1.712.
110
ORIGINAL_ARTICLE
Beneficial Effects of Probiotics in Some of the Important Human Disorders: A narrative review
Probiotics were first proposed by Metchnikoff as contributing factors to health. These living microorganisms, which mainly belong to the microflora bacteria of the gastrointestinal tract, can have beneficial effects on human health if consumed in moderation. The most studied probiotics are lactic acid bacteria, which include Lactobacillus and Bifidobacteria. The present study is an overview of some studies conducted on the effects of using probiotics and their possible patterns in the prevention or reduction of certain human diseases and disorders. The available data suggest that probiotics can play a role in improving constipation and liver enzymes level and functions, and have significant effects on rooting and improving the symptoms of Helicobacter pylori. It was concluded that probiotics have positive effects in metabolic syndrome treatment, preventing gestational diabetes, and improving oral health. Since many probiotics are microorganisms familiar to the gastrointestinal tract, if consumed in moderation, there are no side effects for the host. Using them as complementary therapies for some diseases related to the gastrointestinal tract microflora bacteria can be an effective and low-cost approach to alleviating the annoying symptoms of such diseases.
https://jkmu.kmu.ac.ir/article_91900_edefcb1fe68ebb9237add9709fcecbb1.pdf
2022-03-01
203
217
10.22062/jkmu.2022.91900
probiotics
Constipation
Helicobacter pylori
IBS
Metabolic Syndrome
Gestational diabetes mellitus
NAFLD
Infantile Colic
Behrooz
Talaei
b.talaei@kmu.ac.ir
1
Physiology Research Center, Kerman University of Medical Sciences, Kerman, Iran & Department of Nutrition, School of Public Health, Kerman University of Medical Sciences, Kerman, Iran
LEAD_AUTHOR
Seyed Sina
Ravari
2
2. Student Research Committee, School of Public Health, Kerman University of Medical Sciences, Kerman, Iran & Department of Nutrition, School of Public Health, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
Nariman M. Probiotics, a new generation of living drugs. Research in Medicine. 2008; 32(3):169-74.
1
Bonyadi F, Tukmechi A, Mohebalian H. An overview of probiotics and their role in cancer management. J Mazandaran Univ Med Sci. 2014; 24 (112):128-40. [In Persian].
2
Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: A systematic review. Gut. 2010; 59(3):325-32. doi: 10.1136/gut.2008.167270.
3
Chmielewska A, Szajewska H. Systematic review of randomised controlled trials: Probiotics for functional constipation. World J Gastroenterol. 2010; 16(1):69-75. doi: 10.3748/wjg.v16.i1.69.
4
Didari T, Solki S, Mozaffari S, Nikfar S, Abdollahi M. A systematic review of the safety of probiotics. Expert Opin Drug Saf. 2014; 13(2):227-39. doi: 10.1517/14740338.2014.872627.
5
American Gastroenterological Association, Bharucha AE, Dorn SD, Lembo A, Pressman A. American Gastroenterological Association medical position statement on constipation. Gastroenterology. 2013; 144(1):211-7. doi: 10.1053/j.gastro.2012.10.029.
6
Chatoor D, Emmnauel A. Constipation and evacuation disorders. Best Pract Res Clin Gastroenterol. 2009; 23(4):517-30. doi: 10.1016/j.bpg.2009.05.001.
7
Tack J, Müller-Lissner S, Stanghellini V, Boeckxstaens G, Kamm MA, Simren M, et al. Diagnosis and treatment of chronic constipation-a European perspective. Neurogastroenterol Motil. 2011; 23(8):697-710. doi: 10.1111/j.1365-2982.2011.01709.x.
8
Eoff JC. Optimal treatment of chronic constipation in managed care: Review and roundtable discussion. J Manag Care Pharm. 2008; 14(9):1-15. doi: 10.18553/jmcp.2008.14.S8-A.1.
9
Jahangiri S, Tadayonfar Mar, Rahmani A, Rakhshani Mh. The effect of probiotics on constipation stroke patients admitted To ICU. Journal of Sabzevar University of Medical Sciences. 2016; 23(5):776-81. [In Persian]. doi: 10.21859/sums-2305776.
10
van den Berg MM, Benninga MA, Di Lorenzo C. Epidemiology of childhood constipation: A systematic review. Am J Gastroenterol. 2006; 101(10):2401-9. doi: 10.1111/j.1572-0241.2006.00771.x.
11
American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care. 2011; 34(1):11-61. doi: 10.2337/dc11-S011.
12
Abediny M, Ataiee P, Afkhamzadeh A, Seifmanesh M, Sedaghat B. The effect of probiotics on the treatment of functional constipation in children of 4-12 years of age. Journal of Isfahan Medical School. 2016; 33(368):2448-54. [In Persian].
13
Turan I, Dedeli O, Bor S, İlter T. Effects of a kefir supplement on symptoms, colonic transit, and bowel satisfaction score in patients with chronic constipation: A pilot study. Turk J Gastroenterol. 2014; 25(6):650-6. doi: 10.5152/tjg.2014.6990.
14
Ou Y, Chen S, Ren F, Zhang M, Ge S, Guo H, Zhang H, Zhao L. Lactobacillus casei strain shirota alleviates constipation in adults by increasing the pipecolinic acid level in the Gut. Front Microbiol. 2019; 10:324. doi: 10.3389/fmicb.2019.00324.
15
Indrio F, Di Mauro A, Riezzo G. Prophylactic use of a probiotic in the prevention of colic, regurgitation, and functional constipation--reply. JAMA Pediatr. 2014; 168(8):778. doi: 10.1001/jamapediatrics.2014.368.
16
Dimidi E, Christodoulides S, Fragkos KC, Scott SM, Whelan K. The effect of probiotics on functional constipation in adults: A systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 2014; 100(4):1075-84. doi: 10.3945/ajcn.114.089151.
17
Bekkali NLH, Bongers ME, Van den Berg MM, Liem O, Benninga MA. The role of a probiotics mixture in the treatment of childhood constipation: A pilot study. Nutr J. 2007; 6:17. doi: 10.1186/1475-2891-6-17
18
Favretto DC, Pontin B, Moreira TR. Effect of the consumption of a cheese enriched with probiotic organisms (Bifidobacterium lactis bi-07) in improving symptoms of constipation. Arq Gastroenterol. 2013; 50(3):196-201. doi: 10.1590/S0004-28032013000200035.
19
Jayasimhan S, Yap NY, Roest Y, Rajandram R, Chin KF. Efficacy of microbial cell preparation in improving chronic constipation: A randomized, double-blind, placebo-controlled trial. Clin Nutr. 2013; 32(6):928-34. doi: 10.1016/j.clnu.2013.03.004.
20
Zhang C, Jiang J, Tian F, Zhao J, Zhang H, Zhai Q, et al. Meta-analysis of randomized controlled trials of the effects of probiotics on functional constipation in adults. Clin Nutr. 2020; 39(10):2960-9. doi: 10.1016/j.clnu.2020.01.005.
21
Gold BD, Colletti RB, Abbott M, Czinn SJ, Elitsur Y, Hassall E, et al. Helicobacter pylori infection in children: Recommendations for diagnosis and treatment. J Pediatr Gastroenterol Nutr. 2000; 31(5):490-7. doi: 10.1097/00005176-200011000-00007.
22
Bourke B, Ceponis P, Chiba N, Czinn S, Ferraro R, Fischbach L, et al. Canadian helicobacter study group. canadian helicobacter study group consensus conference: Update on the approach to helicobacter pylori infection in children and adolescents--an evidence-based evaluation. Can J Gastroenterol. 2005; 19(7):399-408.
23
Bhatia SJ, Kochar N, Abraham P, Nair NG, Mehta AP. Lactobacillus acidophilus inhibits growth of Campylobacter pylori in vitro. J Clin Microbiol. 1989; 27(10):2328-30. doi: 10.1128/jcm.27.10.2328-2330.1989.
24
Bernet MF, Brassart D, Neeser JR, Servin A. Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut. 1994; 35(4):483-9. doi: 10.1136/gut.35.4.483.
25
Saneeyan H, Layegh S, Rahimi H. Effectiveness of probiotic on treatment of Helicobacter pylori infection in children. Journal of Isfahan Medical School. 2011; 29(146):882-9.
26
Goderska K, Agudo Pena S, Alarcon T. Helicobacter pylori treatment: Antibiotics or probiotics. Appl Microbiol Biotechnol. 2018; 102(1):1-7. doi: 10.1007/s00253-017-8535-7.
27
Zhang J, Ma S, Wu S, Guo C, Long S, Tan H. Effects of probiotic supplement in pregnant women with gestational diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. J Diabetes Res. 2019; 2019:5364730. doi: 10.1155/2019/5364730.
28
Boltin D. Probiotics in Helicobacter pylori-induced peptic ulcer disease. Best Pract Res Clin Gastroenterol. 2016; 30(1):99-109. doi: 10.1016/j.bpg.2015.12.003.
29
Feng JR, Wang F, Qiu X, McFarland LV, Chen PF, Zhou R, et al. Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a systematic review and network meta-analysis. Eur J Clin Pharmacol. 2017; 73(10):1199-208. doi: 10.1007/s00228-017-2291-6.
30
Fang HR, Zhang GQ, Cheng JY, Li ZY. Efficacy of Lactobacillus-supplemented triple therapy for Helicobacter pylori infection in children: A meta-analysis of randomized controlled trials. Eur J Pediatr. 2019; 178(1):7-16. doi: 10.1007/s00431-018-3282-z.
31
Lionetti E, Miniello VL, Castellaneta SP, Magistá AM, de Canio A, Maurogiovanni G, et al. Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: A randomized placebo controlled trial. Aliment Pharmacol Ther. 2006; 24(10):1461-8. doi: 10.1111/j.1365-2036.2006.03145.x.
32
Song H, Zhou L, Liu D, Ge L, Li Y. Probiotic effect on Helicobacter pylori attachment and inhibition of inflammation in human gastric epithelial cells. Exp Ther Med. 2019; 18(3):1551-62. doi: 10.3892/etm.2019.7742.
33
Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J. Harrison's principles of internal medicine, 19/E (Vol. 1 & Vol. 2). New York: McGraw Hill Professional; 2015.
34
Talley N. Functional gastrointestinal disorders: irritable bowel syndrome, dyspepsia, and noncardiac chest pain. In: Goldman L, Ausiello D. Cecil Textbook of Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier; 2007.
35
Pourfarzi F, Enteshari Mogaddam A, Yazdanbod A, Tazakkori Z, Farzaneh E, Mirzarahimi M. The effect of probiotic yogurt on controlling the symptoms of irritable bowel syndrome . J Ardabil Univ Med Sci. 2011; 11(1):24-32. [In Persian].
36
Francavilla R, Piccolo M, Francavilla A, Polimeno L, Semeraro F, Cristofori F, et al. Clinical and microbiological effect of a multispecies probiotic supplementation in celiac patients with persistent ibs-type symptoms: A randomized, double-blind, placebo-controlled, multicenter trial. J Clin Gastroenterol. 2019; 53(3):117-25. doi: 10.1097/MCG.0000000000001023.
37
Camilleri M. Probiotics and irritable bowel syndrome: Rationale, putative mechanisms, and evidence of clinical efficacy. J Clin Gastroenterol. 2006; 40(3):264-9. doi: 10.1097/00004836-200603000-00020.
38
Didari T, Mozaffari S, Nikfar S, Abdollahi M. Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. World J Gastroenterol. 2015; 21(10):3072-84. doi: 10.3748/wjg.v21.i10.3072.
39
Nikfar S, Rahimi R, Rahimi F, Derakhshani S, Abdollahi M. Efficacy of probiotics in irritable bowel syndrome: A meta-analysis of randomized, controlled trials. Dis Colon Rectum. 2008; 51(12):1775-80. doi: 10.1007/s10350-008-9335-z.
40
Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: Definitions and controversies. BMC Med. 2011; 9:48. doi: 10.1186/1741-7015-9-48.
41
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. International diabetes federation task force on epidemiology and prevention; hational heart, lung, and blood institute; american heart association; world heart federation; international atherosclerosis society; international association for the study of obesity. harmonizing the metabolic syndrome: A joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; american heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation. 2009; 120(16):1640-5. doi: 10.1161/CIRCULATIONAHA.109.192644.
42
Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002; 288(21):2709-16. doi: 10.1001/jama.288.21.2709.
43
Vaghef Mehrabani E, Vaghef Mehrabani L, Norouzi S, Ziyadi S, Homayouni Rad A. The effect of probiotics on prevention and treatment of metabolic syndrome-associated disorders. J Arak Uni Med Sci. 2015; 18(9):74-84. [In Persian].
44
Talaei B, Bahreini S. The effects of cinnamon on diabetes mellitus: A narrative review. IEJM. 2019; 8(1):37-46.
45
Rezazadeh L, Gargari BP, Jafarabadi MA, Alipour B. Effects of probiotic yogurt on glycemic indexes and endothelial dysfunction markers in patients with metabolic syndrome. Nutrition. 2019; 62:162-8. doi: 10.1016/j.nut.2018.12.011.
46
Bernini LJ, Simao ANC, Alfieri DF, Lozovoy MAB, Mari NL, de Souza CHB, et al. Beneficial effects of Bifidobacterium lactis on lipid profile and cytokines in patients with metabolic syndrome: A randomized trial. Effects of probiotics on metabolic syndrome. Nutrition. 2016;32(6):716-9. doi: 10.1016/j.nut.2015.11.001.
47
Sáez-Lara MJ, Robles-Sanchez C, Ruiz-Ojeda FJ, Plaza-Diaz J, Gil A. Effects of probiotics and synbiotics on obesity, insulin resistance syndrome, type 2 diabetes and non-alcoholic fatty liver disease: A review of human clinical trials. Int J Mol Sci. 2016; 17(6):928. doi: 10.3390/ijms17060928.
48
Stadlbauer V, Leber B, Lemesch S, Trajanoski S, Bashir M, Horvath A, et al,. Lactobacillus casei shirota supplementation does not restore gut microbiota composition and gut barrier in metabolic syndrome: A randomized pilot study. PLoS One. 2015; 10(10):0141399. doi: 10.1371/journal.pone.0141399.
49
Leber B, Tripolt NJ, Blattl D, Eder M, Wascher TC, Pieber TR, et al. The influence of probiotic supplementation on gut permeability in patients with metabolic syndrome: An open label, randomized pilot study. Eur J Clin Nutr. 2012; 66(10):1110-5. doi: 10.1038/ejcn.2012.103.
50
Barreto FM, Colado Simão AN, Morimoto HK, Batisti Lozovoy MA, Dichi I, Helena da Silva Miglioranza L. Beneficial effects of Lactobacillus plantarum on glycemia and homocysteine levels in postmenopausal women with metabolic syndrome. Nutrition. 2014; 30(7-8):939-42. doi: 10.1016/j.nut.2013.12.004.
51
He M, Shi B. Gut microbiota as a potential target of metabolic syndrome: The role of probiotics and prebiotics. Cell Biosci. 2017; 7:54. doi: 10.1186/s13578-017-0183-1.
52
Mahan LK, Escott-Stump S. Krause's food & nutrition therapy. 12th Edition. Saunders Elsevier, St. Louis; 2008.
53
Koren O, Goodrich JK, Cullender TC, Spor A, Laitinen K, Bäckhed HK,et al. Host remodeling of the gut microbiome and metabolic changes during pregnancy. Cell. 2012; 150(3):470-80. doi: 10.1016/j.cell.2012.07.008.
54
Yadav H, Jain S, Sinha PR. Oral administration of dahi containing probiotic Lactobacillus acidophilus and Lactobacillus casei delayed the progression of streptozotocin-induced diabetes in rats. J Dairy Res. 2008; 75(2):189-95. doi: 10.1017/S0022029908003129.
55
Zhang J, Ma S, Wu S, Guo C, Long S, Tan H. Effects of probiotic supplement in pregnant women with gestational diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. J Diabetes Res. 2019; 2019:5364730. doi: 10.1155/2019/5364730.
56
Kijmanawat A, Panburana P, Reutrakul S, Tangshewinsirikul C. Effects of probiotic supplements on insulin resistance in gestational diabetes mellitus: A double-blind randomized controlled trial. J Diabetes Investig. 2019; 10(1):163-70. doi: 10.1111/jdi.12863.
57
Taylor BL, Woodfall GE, Sheedy KE, O'Riley ML, Rainbow KA, Bramwell EL, et al. Effect of Probiotics on Metabolic Outcomes in Pregnant Women with Gestational Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients. 2017; 9(5):461. doi: 10.3390/nu9050461.
58
Pan J, Pan Q, Chen Y, Zhang H, Zheng X. Efficacy of probiotic supplement for gestational diabetes mellitus: A systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2019; 32(2):317-23. doi: 10.1080/14767058.2017.1376318.
59
Hajifaraji M, Dolatkhah N. Probiotics and metabolic outcomes of gestational diabetes: A review article. J Mazandaran Univ Med Sci. 2018; 28(162):155-74.
60
Jameshorani M, Rafiee E, Kamali K. Treatment effects of probiotic in non alcoholic fatty liver disease. J Adv Med Biomed Res. 2017; 25(109):23-35. [In Persian].
61
Nabavi S, Rafraf M, Somi MH, Homayouni-Rad A, Asghari-Jafarabadi M. Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease. J Dairy Sci. 2014; 97(12):7386-93. doi: 10.3168/jds.2014-8500.
62
Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: A double blind randomized clinical trial. Eur Rev Med Pharmacol Sci. 2011; 15(9):1090-5. PMID: 22013734.
63
Xue L, He J, Gao N, Lu X, Li M, Wu X, et al. Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia. Sci Rep. 2017; 7:45176. doi: 10.1038/srep45176.
64
Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: A meta-analysis. World J Gastroenterol. 2013;19(40):6911-8.doi: 10.3748/wjg.v19.i40.6911.
65
Davari M, Hashemi R, Mirmiran P, Hedayati M, Sahranavard S, Bahreini S, et al. Effects of cinnamon supplementation on expression of systemic inflammation factors, NF-kB and Sirtuin-1 (SIRT1) in type 2 diabetes: A randomized, double blind, and controlled clinical trial. Nutr J. 2020; 19(1):1. doi: 10.1186/s12937-019-0518-3.
66
Ipar N, Aydogdu SD, Yildirim GK, Inal M, Gies I, Vandenplas Y, Dinleyici EC. Effects of synbiotic on anthropometry, lipid profile and oxidative stress in obese children. Benef Microbes. 2015; 6(6):775-82. doi: 10.3920/BM2015.0011.
67
Rajkumar H, Mahmood N, Kumar M, Varikuti SR, Challa HR, Myakala SP. Effect of probiotic (VSL#3) and omega-3 on lipid profile, insulin sensitivity, inflammatory markers, and gut colonization in overweight adults: A randomized, controlled trial. Mediators Inflamm. 2014; 2014:348959. doi: 10.1155/2014/348959.
68
Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology. 2003; 37(2):343-50. doi: 10.1053/jhep.2003.50048.
69
Famouri F, Shariat Z, Hashemipour M, Keikha M, Kelishadi R. Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents. J Pediatr Gastroenterol Nutr. 2017; 64(3):413-7. doi: 10.1097/MPG.0000000000001422.
70
Gao X, Zhu Y, Wen Y, Liu G, Wan C. Efficacy of probiotics in non-alcoholic fatty liver disease in adult and children: A meta-analysis of randomized controlled trials. Hepatol Res. 2016; 46(12):1226-33. doi: 10.1111/hepr.12671.
71
Wessel MA, Cobb JC, Jackson EB, Harris GS Jr, Detwiler AC. Paroxysmal fussing in infancy, sometimes called colic. Pediatrics. 1954; 14(5):421-35. PMID: 13214956.
72
Rafeey M, Mostafa Gharehbaghi M, Shoaran M, Gholshaian F. Survey in efficacy of probiotics in infantile colic. Research in Medicine. 2016; 40(3):135-42.
73
Chau K, Lau E, Greenberg S, Jacobson S, Yazdani-Brojeni P, Verma N, et al. Probiotics for infantile colic: A randomized, double-blind, placebo-controlled trial investigating Lactobacillus reuteri DSM 17938. J Pediatr. 2015; 166(1):74-8. doi: 10.1016/j.jpeds.2014.09.020.
74
Kianifar H, Ahanchian H, Grover Z, Jafari S, Noorbakhsh Z, Khakshour A, et al. Synbiotic in the management of infantile colic: A randomised controlled trial. J Paediatr Child Health. 2014; 50(10):801-5. doi: 10.1111/jpc.12640.
75
Saavedra JM, Abi-Hanna A, Moore N, Yolken RH. Long-term consumption of infant formulas containing live probiotic bacteria: Tolerance and safety. Am J Clin Nutr. 2004; 79(2):261-7. doi: 10.1093/ajcn/79.2.261.
76
Schreck Bird A, Gregory PJ, Jalloh MA, Risoldi Cochrane Z, Hein DJ. Probiotics for the treatment of infantile colic: A systematic review. J Pharm Pract. 2017; 30(3):366-74. doi: 10.1177/0897190016634516.
77
Sung V. Probiotic interventions in infantile colic. Curr Opin Clin Nutr Metab Care. 2015; 18(3):307-11. doi: 10.1097/MCO.0000000000000157.
78
Anabrees J, Indrio F, Paes B, AlFaleh K. Probiotics for infantile colic: A systematic review. BMC Pediatr. 2013; 13:186. doi: 10.1186/1471-2431-13-186.
79
Meurman JH, Stamatova I. Probiotics: contributions to oral health. Oral Dis. 2007; 13(5):443-51. doi: 10.1111/j.1601-0825.2007.01386.x.
80
Busscher HJ, Mulder AF, van der Mei HC. In vitro adhesion to enamel and in vivo colonization of tooth surfaces by Lactobacilli from a bio-yoghurt. Caries Res. 1999; 33(5):403-4. doi: 10.1159/000016541.
81
Haukioja A, Yli-Knuuttila H, Loimaranta V, Kari K, Ouwehand AC, Meurman JH, et al. Oral adhesion and survival of probiotic and other lactobacilli and bifidobacteria in vitro. Oral Microbiol Immunol. 2006; 21(5):326-32. doi: 10.1111/j.1399-302X.2006.00299.x.
82
Hatakka K, Ahola AJ, Yli-Knuuttila H, Richardson M, Poussa T, Meurman JH, et al. Probiotics reduce the prevalence of oral candida in the elderly--a randomized controlled trial. J Dent Res. 2007; 86(2):125-30. doi: 10.1177/154405910708600204.
83
Tsubura S, Mizunuma H, Ishikawa S, Oyake I, Okabayashi M, Katoh K, et al. The effect of Bacillus subtilis mouth rinsing in patients with periodontitis. Eur J Clin Microbiol Infect Dis. 2009; 28(11):1353-6. doi: 10.1007/s10096-009-0790-9.
84
Matsubara VH, Bandara HM, Ishikawa KH, Mayer MP, Samaranayake LP. The role of probiotic bacteria in managing periodontal disease: A systematic review. Expert Rev Anti Infect Ther. 2016; 14(7):643-55. doi: 10.1080/14787210.2016.1194198.
85
Stamatova I, Meurman JH. Probiotics: health benefits in the mouth. Am J Dent. 2009; 22(6):329-38. PMID: 20178208.
86
Saxelin M, Tynkkynen S, Mattila-Sandholm T, de Vos WM. Probiotic and other functional microbes: from markets to mechanisms. Curr Opin Biotechnol. 2005; 16(2):204-11. doi: 10.1016/j.copbio.2005.02.003.
87
Kunz AN, Noel JM, Fairchok MP. Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome. J Pediatr Gastroenterol Nutr. 2004; 38(4):457-8. doi: 10.1097/00005176-200404000-00017.
88
De Groote MA, Frank DN, Dowell E, Glode MP, Pace NR. Lactobacillus rhamnosus GG bacteremia associated with probiotic use in a child with short gut syndrome. Pediatr Infect Dis J. 2005; 24(3):278-80. doi: 10.1097/01.inf.0000154588.79356.e6.
89
Land MH, Rouster-Stevens K, Woods CR, Cannon ML, Cnota J, Shetty AK. Lactobacillus sepsis associated with probiotic therapy. Pediatrics. 2005; 115(1):178-81. doi: 10.1542/peds.2004-2137.
90
Pletincx M, Legein J, Vandenplas Y. Fungemia with Saccharomyces boulardii in a 1-year-old girl with protracted diarrhea. J Pediatr Gastroenterol Nutr. 1995; 21(1):113-5. doi: 10.1097/00005176-199507000-00022.
91
Burkhardt O, Köhnlein T, Pletz M, Welte T. Saccharomyces boulardii induced sepsis: successful therapy with voriconazole after treatment failure with fluconazole. Scand J Infect Dis. 2005; 37(1):69-72. doi: 10.1080/00365540510026454.
92
Rijnders BJ, Van Wijngaerden E, Verwaest C, Peetermans WE. Saccharomyces fungemia complicating Saccharomyces boulardii treatment in a non-immunocompromised host. Intensive Care Med. 2000; 26(6):825. doi: 10.1007/s001340051261.
93
Prasanna PHP, Grandison AS, Charalampopoulos Bifidobacteria in milk products: An overview of physiological and biochemical properties, exopolysaccharide production, selection criteria of milk products and health benefits. Food Research International. 2014; 55:247-62. doi: 10.1016/j.foodres.2013.11.013.
94
Nami Y, Haghshenas B, Vaseghi Bakhshayesh R, Mohammadzadeh Jalaly H, Lotfi H, Eslami S, et al. Novel autochthonous lactobacilli with probiotic aptitudes as a main starter culture for probiotic fermented milk. LWT. 2018; 98: 85-93. doi: 10.1016/J.LWT.2018.08.035.
95
Jeon HL, Yang S-J, Son SH, Kim WS, Lee NK, Paik H-D. Evaluation of probiotic Bacillus subtilis P229 isolated from cheonggukjang and its application in soybean fermentation. LWT. 2018; 97:94-9. doi: 10.1016/j.lwt.2018.06.054.
96